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VI   : Visual Inspection 
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NILM           : Negative for Intraepithelial Lesion or Malignancy  
ASCUS         : Atypical Squamous Cells of Undetermined Significance 
ASC-H          : Atypical Squamous Cells, cannot exclude HSIL 
SIL                : Squamous Intraepithelial Lesion 
LSIL             : Low grade Squamous Intraepithelial Lesion 
HSIL             : High grade Squamous Intraepithelial Lesion 
SCC              : Squamous cell carcinoma 
AIS               : Adenocarcinoma- In-Situ 
Rb                 : Retinoblastoma 
ALTS            : Atypical squamous cells/Low grade squamous   
      intraepithelial Lesion Triage Study  
NCI               : National cancer institute 
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INTRODUCTION
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INTRODUCTION 
Carcinoma cervix is one of the leading causes of death among 
women in developing countries. For each case of cancer of body of the 
uterus, there are 25 cases of cancer cervix in India. About 5,00,000  new 
cases of carcinoma cervix are being diagnosed each year out of which 
79% occur in the developing countries
1
. The 5 years survival rate is 90% 
for cervical cancer in the early stage whereas it is much lower (14%) for 
persons with advanced stage IV disease. The incidence of invasive 
cervical cancer has come down to a great extent over a span of 40 years, 
mainly because of early cancer detection programs. A close quarters 
observation on the social behaviour of our society reveals that most of the 
women in our country have their marriages at very early part of their life 
leading to early commencement of sexual activity and poor sexual 
hygiene which are considered to be important etiological factors for 
cervical carcinoma
2
.  
INCIDENCE 
In India, the age standardised incidence rate of carcinoma cervix is 
30.7 per 100,000 women and the global age standardised incidence rate is 
16 per 100,000
1
. The death rate of cervical cancer in India is 6.5 per 
1,00,000. 
PREVALENCE 
A conservative estimate of global prevalence states that there are 
about 1.7 million cases of clinically recognized cervical cancer and 5-13 
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million women have precancerous lesions. This estimate is high owing to 
the addition of new cases each year and also due to the fact that the 
diagnosed cases do not receive adequate treatment. Current resources 
about the natural history of cancer cervix suggest that there are two to 
five times women with potential precursors to cervical cancer such as 
those with invasive cervical carcinoma. This results in a rough estimate of 
7,000,000 women around the world with high-grade dysplasia requiring 
detection and treatment. 
CAUSES OF SCREENING FAILURE IN DEVELOPING 
COUNTRIES: 
 A number of women with cervical cancer do not turn up for 
investigations  and hence are excluded from the cancer registry data 
resulting in considerably lower estimates of statistical parameters 
like cancer incidence, prevalence, and disease related mortality.  
 Diagnostic facilities do not reach older women or those with 
financial constraint which pose a great challenge in estimating the 
current statistics. 
 Recording the number of women with cervical cancer is 
problematic
2
 because of the lack of organized health information 
systems in developing countries like India.    
  
 
 
 
 
AIMS AND 
OBJECTIVES
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AIMS AND OBJECTIVES 
 To compare the efficacy of VIA, VILI, conventional Pap smear 
and LiquiPrepTM as screening procedure for carcinoma cervix in 
patients attending the Gynecology department of Institute of social 
obstetrics and Govt. Kasturba Gandhi hospital,Chennai. 
 To study abnormal smears and do cervical biopsy for those 
patients. 
 To correlate the cytological findings with histopathological 
diagnosis. 
 To evaluate the advantages and disadvantages of conventional Pap 
and LiquiPrep
TM
 in the screening of cervical lesions. 
 
 
           
                          
 
 
 
 
 
Review of 
literature
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REVIEW OF LITERATURE 
Cervical cancer is ranked the first among cancers arising in women 
of the Indian subcontinent, accounting for about 26.1- 43.8% of all 
carcinomas in Indian women
2
. By virtue of its accessibility, cancer of 
cervix can be readily diagnosed in its precancerous stage. If treated in the 
earlier stages the patient can often be cured of the disease. There are 
various methods of screening for carcinoma cervix. 
Gathering data from national programs organized in eight 
countries, the International Agency for Research on Cancer (IARC) 
reported a 90% reduction in the incidence of cervical carcinoma if the 
entire female population is screened at regular intervals
3
.
   
RISK FACTORS ASSOCIATED WITH SIL: 
 Number of sexual partners 
 Age at first intercourse (especially less than 16 years of age) 
 Sexually transmitted diseases- Human papillomavirus, Herpes 
simplex virus, Chlamydia trachomatis 
 Early age of first pregnancy 
 Parity 
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 Low socioeconomic class 
 Cigarette smoking 
 Human immunodeficiency virus 
 Immunosuppression from any cause 
 Deficiencies of vitamins 
 Interval between the pap smears 
 Use of oral contraceptives  
In a study by Parazzini F et al
4
 the number of sexual partners and 
commencement of early sexual activity were independent risk factors for 
development of carcinoma cervix. 
Walboomers JM et al
5
 proved the viral aetiology of cancer cervix 
beyond doubt.  
Schiffman et al
6
 showed that among those women infected with 
high-risk types of HPV, the risk can be doubled if associated with other 
factors such as smoking,  immunosuppression, and long-term use of oral            
contraceptives. 
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 NATURAL HISTORY OF DISEASE: 
Understanding the natural history of various stages of CIN is the 
cornerstone for the appropriate clinical management. In addition to the 
degree of dysplasia, it is likely that the course of a specific lesion is also 
influenced by other factors such as the patient‟s age, inciting HPV type, 
immune competence and smoking 
6 . 
 
 
 
 
HUMAN PAPILLOMAVIRUS AND THE PATHOGENESIS OF 
PRECURSOR LESIONS AND CERVICAL CARCINOMA 
 Papanicolaou (1954) was the first person to report on the 
“perinuclear cavitation” while Koss and Durfee (1956)7 have 
commented on the HPV induced change as “koilocytotic 
vacuolated change”  
 Purola and Savia8 (1977) published their paper on distinctive 
morphologic lesions in the uterine cervix with characteristic 
cytopathic effects of HPV similar to the changes seen in genital 
warts (condylomata accuminata). 
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 More than 99% of all cervical cancers are considered to be related 
to HPV independent of racial origin
9
.  
 HPV is a double-stranded DNA virus and a member of the 
Papovaviridae family. The various subtypes of HPV are divided 
into “low-risk” and “high-risk” depending on the risk of carcinoma 
associated with the infection. Low-risk subtypes are 6, 11, 42, 43, 
44, and 53, whereas high-risk subtypes include 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56,58, 59, and 68
6
.  
 The human papilloma virus enters the basal cells or immature 
squamous metaplastic cells via the mucosal defects in the 
transformation zone.  
 The virus may cause either a nonproductive (latent) or a productive 
infection.  
 In productive infection, large amounts of free DNA virus 
(episomal) are produced in the intermediate and superficial cell 
layers. The infected cells mature and migrate towards the surface 
making obvious the characteristic cytopathic effect – the koilocytic 
atypia.  
 Integration of HPV DNA into the host cell genome, with covalent 
binding of viral genome into host DNA, is a critical event in the 
progression to high-grade squamous intraepithelial lesions (HSIL). 
 High-risk HPVs produce two proteins E6 and E7, with growth-
stimulating and transforming properties. Viral integration into the 
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host cell genome results in disruption of the viral DNA with 
overexpression of E6/E7 genes.  
 In a study by Werness BA et al10, increased levels of the E6/E7 
viral oncoproteins result in abrogation of p53/Rb tumour 
suppressor proteins, resulting in uncontrolled cell cycling and 
proliferative activity of the squamous epithelium.
 
 It is stated that low-risk HPV is commonly associated with low-
grade squamous intraepithelial lesions (LSIL) which frequently 
regresses, whereas high-risk HPV subtypes can result in either 
LSIL or HSIL. Moreover, if untreated, HSIL can subsequently 
progress to invasive carcinoma
11
. 
 
 However, a recent multicenter study (“Atypical squamous 
cells/Low grade squamous intraepithelial lesion Triage Study 
(ALTS)”) has shown that in contrast to previous findings, 83% of 
women with a LSIL on Pap test had a high-risk HPV subtype. 
 
 Hence, abnormalities associated with HPV may be classified into 
transient infections regressing over the course of 1 to 2 years and 
persistent infections which are associated with an increasing risk of 
development of a precursor lesions of cervical cancer or invasive 
cancer.
12,13 
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APPROXIMATE VALUE OF SPONTANEOUS REGRESSION OR 
PERSISTENCE AND PROGRESSION OF CIN
14
:  
COURSE OF CIN CIN 1 CIN 2 CIN 3 
REGRESSION TO NORMAL 60% 40-50% 33% 
PERSISTENCE 30% 40% 55% 
PROGRESSION TO CANCER 1% 5% >12% 
 
SCREENING METHODS FOR CERVICAL CANCER 
 Visual screening approaches- Colposcopy 
 Conventional Pap Smear 
  Liquid Based Cytology 
 Automated screening 
 HPV Genotyping 
VISUAL SCREENING APPROACHES: 
         Visual screening is a process by which cervical lesions are 
identified without relying on cytology. Early studies included visual 
inspection (VI), which involved simply visualising the cervix with the 
unaided eye to detect any signs of early cancer. Also referred to as 
10 
 
“downstaging,” this strategy was not much precise in detecting the cancer 
precursors.  
Pathophysiological basis of VIA: 
When acetic acid is applied, normal squamous epithelium presents 
a pink hue while the columnar epithelium is bright red owing to the 
reflection of light by the highly vascular stroma. Whitening effect of 
acetic acid is proportional to the amount of cellular proteins. Areas with 
the highest nuclear activity and DNA content demonstrate the most 
dramatic change in colour. Inflammation and healing result in acetowhite 
areas that are distributed widely and are restricted to transformation zone 
and quickly disappears. Acetowhitening of CIN takes up promptly and 
reverses slowly. 
Pathophysiological basis of VILI: 
On applying iodine, normal squamous epithelium turns mahogany 
brown since it is glycogen rich. Columnar epithelium is unstained since it 
does not take up iodine. Areas of CIN and invasive cancer do not stain 
with iodine and remain saffron coloured or mustard yellow. 
Brief history of colposcopy
16 
Colposcopy was introduced by Hans Heinselmann in 1925 at 
Germany. He stated that it might be possible to detect cervical cancer at 
11 
 
an early stage by adequate  illumination and magnification of the cervix. 
In 1928, Schiller introduced the concept of applying iodine on the cervix 
to identify unstained glycogen depleted areas for biopsy. 
 
Indications for colposcopy: 
 Suspicious looking cervix 
 CIN1, CIN 2, CIN 3 or invasive carcinoma on cytology 
 Persisting low grade abnormalities 
 Persistently unsatisfactory quality on cytology 
 HPV infection 
 Acetowhite areas on VIA 
 Positive lesion on VILI 
Advantages of colposcopy: 
 Promising tool in low resource settings 
 Simple approach 
 Not much dependent on infrastructure for adequate performance 
 Maintenance is easier and cheaper 
12 
 
 Both diagnostic and therapeutic procedures can be done. 
 Location of the lesions 
 Selection of biopsy site 
 Determination of treatment of early invasive cancer 
and CIN 
 Reduction in unnecessary biopsy 
 Management of abnormal smear in pregnancy 
Disadvantages of colposcopy: 
 Low specificity when used in asymptomatic women17. 
 Cost and maintenance of the equipment. 
 Time and skill necessary to do the procedure and interpret the 
findings. 
REPORTING VISUAL INSPECTION FINDINGS
18
 
NORMAL 
 Smooth, Pink. 
 External Os: Central Hole, Round – Nullipara, Slit –Multipara. 
 Atrophic – Post Menopausal. 
13 
 
ABNORMAL 
 Infection : Hypertrophy. 
 Ectopy : Redness / Congestion 
 Distortion, simple erosions (Does not bleed on touch) 
 Cervical polyps (With smooth surface) 
 Abnormal discharge (foul smelling, dirty white greenish) 
 Nabothian follicles 
 Suspicious of Maligancy: Lesions that bleeds on touch /irregular 
surface, friable growth 
VIA Positive Acetowhite areas present. 
VIA Negative No acetowhite areas. 
Various categories are used to classify visual inspection findings. 
Category Results 
 Ulcerative or exophytic cervical growth suspicious of carcinoma 
 Definite Lesion: Acetowhite lesion with well defined border 
                                      Non confluent scattered lesion 
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 Focal: small, punctuated areas of acetowhitening 
 Ill defined lesion: Vaguely defined and faintly acetowhite 
 No Lesion: No acetowhite lesion 
Negative VILI 
 Normal Cervix 
 Polyps: Areas which appear pale due to no/partial iodine uptake  
 Leopard skin appearance is seen in Trichomonas Vaginalis 
infection 
 Satellite lesions: Areas which do not show iodine uptake are seen 
away from the squamocolumnar junction. 
Positive VILI 
The result is recorded as positive when dense, bright mustard 
yellow or saffron –yellow coloured iodine negative areas are visible in 
the tranformation zone around the squamocolumnar junction or when the 
entire cervix turns dense yellow. 
VILI Positive (Invasive Cancer) 
When an irregular, ulcerative or proliferative growth is present on 
the cervix which changes to yellow colour on application of iodine. 
15 
 
HISTORY AND RECENT ADVANCES IN PAP SMEAR: 
 In 1851, Robert Hull, introduced the use of vaginal speculum 
which helped to reveal an epidemic of uterine disease. 
 While studying the response of the human vaginal mucosa to 
hormones, George Papanicolaou discovered that tumor cells can be 
detected in the vaginal fluid of patients of cervical carcinoma
19
. 
Papanicolaou published this paper entitled "New Cancer 
Diagnosis" in 1928
20
.  
  Aurel Babès, a Romanian pathologist, presented his paper entitled 
"The possibility of diagnosing uterine cancer by the smear technic" 
in 1927
21
. Babès elaborated on this paper in April 1928 and clearly 
stated that his method was applicable to early cancers which had 
not penetrated the stroma. Later, Kermauner and Schiller had used 
a modified vaginal smear method for the diagnosis of carcinoma 
cervix on a large scale with good results
22
. 
  It was actually a Canadian physician by name J. Ernest Ayre who 
first studied the procedure which is called pap smear at present in 
the mid-1940s
23
.  
  In 1943 J.Ernest Ayre et al, emphasized on the use of cervical os 
aspiration as a preferable technique for the diagnosis of uterine 
cancer and published „A simple office test for uterine cancer 
diagnoses‟. 
16 
 
  In 1947, Ayre et al used surface biopsy cell scrapping technique 
with Ayre‟s spatula24.  
 A conventional pap smear or liquid-based cytology test is the test 
which is routinely employed for detecting precursor lesions of 
cervical carcinoma in the cervical cells. 
CELL COMPONENTS IN A PAP SMEAR 
Basal cells - rarely seen except in atrophic vagina. Small round 
cells with smooth border and a central round nucleus. 
Parabasal cells - uniform round cells with a thick blue or green 
cytoplasm and large central round nucleus. 
Intermediate cells - polyhedral cells with thin semitransparent 
pink to blue cytoplasm and central large vesicular nucleus. A folding or 
curling tendency of the edges (navicular cells) is seen in pregnancy. 
Superficial cells - most common and largest epithelial cell in a pap 
smear. Polyhedral cells with a thin homogenous cytoplasm pink to orange 
(if keratin is present). Nucleus is central and pyknotic. 
Endocervical cells - ciliated or nonciliated cells, honeycomb or 
picket-fence pattern depending on the view. 
Endometrial cells - can also be seen depending on the site of 
collection. 
17 
 
PAP SMEAR NOMENCLATURE
25
: 
Papanicolaou 
Class system 
(1954) 
Descriptive 
(1968) 
CIN 
(1978) 
Bethesda system 
(1988) 
Class I Negative for  
malignant cells 
Negative Within normal limits 
Class II Inflammatory 
atypia 
 
Squamous atypia 
Koilocytic atypia 
Negative Reactive and 
reparative changes 
 
Atypical squamous 
cells of undetermined 
significance 
Class III Mild dysplasia 
Moderate 
dysplasia 
Severe dysplasia 
CIN I 
CIN II 
 
CIN III 
LSIL 
HSIL 
 
HSIL 
Class IV Carcinoma in situ CIN III HSIL 
Class V Invasive 
carcinoma 
Invasive 
carcinoma 
Invasive carcinoma 
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THE BETHESDA SYSTEM
26 
As seen above, the terminology used in cervical cytology has 
evolved over the course of many years. In1988, National cancer institute 
(NCI) working groups coined uniform descriptive terminology for 
cervical cytology and named it as „The Bethesda System (TBS)‟.The 
1988 Bethesda system of reporting cervix/vaginal cytology divided 
squamous intra epithelial lesions into the following categories. 
1. Atypical squamous cells of undetermined significance (ASCUS) 
2. Low Grade SIL 
3. High Grade SIL 
4. Squamous cell carcinoma 
The main criticism of this system was that many individuals whose 
smears were designated Low Grade SIL category were overtreated. 
Hence minor changes were made in the 1991 Bethesda system which 
modified the terminology. The committee also laid down criteria for 
adequacy of the specimen and diagnostic terms in a TBS atlas which 
outlines and illustrates the important cytologic features. The Bethesda 
System (2001) is currently in use. 
19 
 
The Bethesda System includes three factors namely, 
a. Statement of specimen adequacy 
b. General categorization 
c. Diagnostic terminology 
A. SPECIMEN ADEQUACY 
An adequate specimen is described in positive terms as a correctly 
labelled one, provided with the necessary clinical information, adequately 
fixed and on microscopic examination demonstrates an appropriate 
number of well preserved and evenly distributed cells which includes an 
ectocervical and an endocervical component. For conventional pap, 
minimum of 8,000-12,000 and for liquid based cytology a minimum of 
5,000 squamous epithelial cells which are adequately preserved and well 
visualized are considered to be “satisfactory for evaluation”. An adequate 
endocervical / transformation zone component consists of ten well 
preserved cells occurring individually or in groups. Mitchell and 
Medley
27 
proved that the presence of endocervical cells is not a criterion 
when the detection rate of endocervical cells is high, especially when a 
cytobrush is used. 
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B. GENERAL CATEGORIZATION 
1. NEGATIVE FOR INTRAEPITHELIAL LESION OR 
MALIGNANCY 
Smears with no epithelial abnormality are recorded as “Negative 
for intraepithelial lesion or malignancy” (NILM). 
o Infections:  
 Trichomonas vaginalis 
 Fungal organisms morphologically consistent with Candida 
  species. 
 Shift in flora suggestive of bacterial vaginosis 
 Bacteria morphologically consistent with Actinomyces  
  species. 
 Cellular changes consistent with herpes simplex virus 
o Reactive cellular changes:  
Reparative change can manifest as regeneration of cells which 
involves the squamous epithelium, squamous metaplastic epithelium and 
columnar epithelium.  
21 
 
Reparative reactions are frequent in women with recurrent 
cervicitis and recent treatment such as conization, punch biopsies, laser 
therapy, cryosurgery and endocervical curettage. 
Colgan et al
28
 suggested that cells from reparative epithelium lack 
reproducibility and appear as sheet like aggregates with ill defined 
cytoplasmic borders.  
The cytoplasm is finely vacuolated and cyanophilic.  
Nuclei appear round to oval with variable degree of nuclear 
enlargement and altered size of nuclei. The cells have prominent nucleoli 
with evenly distributed and finely granular chromatin but the nuclei are 
not hyperchromatic. 
2. EPITHELIAL ABNORMALITES 
ASCUS (ATYPICAL SQUAMOUS CELLS OF UNDERTERMINED 
SIGNIFICANCE) 
 ASC refers to smears in which the cytologic changes suggest SIL, 
but are insufficient either qualitatively or quantitatively to give a 
definitive interpretation
29
. 
22 
 
 Criteria 
o Nuclei are about two and a half to three times the size of the 
nucleus of a normal intermediate type of squamous cell 
30
. 
o Mild increase in nuclear cytoplasmic ratio. 
o There is minimal nuclear hyperchromasia and mildly 
irregular chromatin distribution. 
ATYPICAL SQUAMOUS CELLS, CANNOT EXCLUDE HSIL 
(ASC-H)  
 Criteria 
o Cells occur singly or in small fragments of less than 10 cells. 
o Cells approximate the size of metaplastic cells with nucleus of 
size 1½ to 2½ times larger than normal. Nuclear cytoplasmic 
ratio may be similar to that of HSIL. 
o Nuclear variations like chromatin irregularity, hyperchromasia, 
and altered nuclear shapes showing focal irregularity are in 
favour of HSIL. 
o The rate of ASCUS is generally less than 5% in low risk 
population. The rate of ASCUS although higher in high risk 
population, it should not be more than two to three times the 
percentage of SIL. 
23 
 
o Sherman ME et al31 concluded that in 25% to 60 % of patients 
with ASCUS, further evaluation will detect a squamous 
intraepithelial lesion. 
SQUAMOUS INTRA EPITHELIAL LESIONS (SIL) 
In the Bethesda system, low grade squamous intraepithelial lesion 
(LSIL) and high grade squamous intra epithelial lesion (HSIL) constitute 
the spectrum of precursor lesions of cancer cervix.  
LSIL: 
CYTOLOGY 
 Changes in the squamous cell associated with HPV infection 
include “mild dysplasia” and “CIN 1.”  
 Both lesions exhibit similarity in biologic behaviour, inciting HPV 
types and clinical management, thereby coming under a common 
terminology of LSIL
32,33
. 
 Criteria 
o Reagan et al34 demonstrated that cytologic changes of LSIL 
are usually limited to “mature” or superficial-type of cells 
and the cells occur in sheets and in singles.  
24 
 
o Nuclear enlargement more than three times the size of the 
nucleus of a normal intermediate cell nuclei resulting in a 
slightly higher nuclear cytoplasmic ratio. 
o Binucleation and multinucleation are common. 
o Chromatin is coarsely granular and the nuclear membrane is 
mildly irregular with inconspicuous nucleoli. 
o A markedly delineated clear perinuclear zone and a 
peripheral rim of densely stained cytoplasm constitute the 
perinuclear cavitation (“koilocytosis”) which is a typical 
feature. 
HISTOPATHOLOGY 
Stratification is well preserved with regular orientation of the cells 
in the upper two thirds of the epithelium. The middle and upper layers are 
predominantly composed of superficial type and intermediate type cells 
with mildly reduced cytoplasmic area and slight increase in the nuclear 
size. Aberrations of nuclear cytology are limited only to the most basal 
layers of the squamous epithelium. 
25 
 
HIGH GRADE SIL (CIN-2 AND CIN-3) 
CYTOLOGY 
 Criteria 
o Cytologic changes are seen in the cells that are comparatively 
smaller and immature in contrast to those seen in LSIL. 
o Cells occur in sheets, in syncytial aggregates or in singles 
demonstrating hyperchromasia of nuclei along with alterations in 
nuclear size and shape. 
o There is variable nuclear enlargement and decrease in cytoplasmic 
area, leading to a markedly increased nuclear/cytoplasmic ratio.  
o Chromatin demonstrates fine or coarse granularity and the nuclear 
membrane shows prominent grooves or indentations. 
o Nucleoli though usually inconspicuous, may occasionally be seen. 
HISTOPATHOLOGY 
In CIN 2 stratification of cells is preserved in the upper one third of 
the epithelium. Cell orientation is disturbed in the lower two thirds of the 
squamous epithelium.  
In CIN 3, cell arrangement is disturbed in all the layers of the 
epithelium with the cells exhibiting decreased cytoplasmic volume and an 
increase in nuclear size with variable shapes and also irregular forms. 
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Carcinoma in situ refers to a lesion replacing the normal surface 
epithelium with all the layers of the epithelium showing cells exhibiting 
poorly differentiated or largely undifferentiated cells
21
 but invasion is 
absent. 
INVASIVE CANCER OF THE UTERINE CERVIX 
CYTOLOGY 
 Criteria 
o Cells show poorly defined borders and are arranged in sheets.  
o Nuclei are round to oval nuclei and show irregularly clumped 
chromatin and macronucleoli.  
o Eosinophilic cytoplasm seen. 
o Tadpole cells and other bizarre forms may be observed. 
ATYPICAL ENDOCERVICAL CELLS OF UNDETERMINED 
SIGNIFICANCE 
 Criteria 
o Endocervical cells which lack unequivocal features of malignancy 
but which show nuclear atypia which is more obvious than that 
seen in reactive or reparative changes.  
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Atypical Endocervical Cells: NOS  
 Criteria 
o Cells show nuclear crowding and overlapping and arranged in 
sheets. 
o Nucleus size is of three to five times the size of normal 
endocervical nuclei with hyperchromasia and prominent nucleoli.  
o There is increased nuclear cytoplasmic ratio inspite of the abundant 
cytoplasm. 
Atypical Endocervical Cells, Favor Neoplastic  
 Cell morphology falls just short of a diagnosis of in situ or invasive 
endocervical adenocarcinoma. 
 Criteria 
o Abnormal cells in sheets and strips with nuclear crowding. 
o Nucleus is large and hyperchromatic with few mitotic figures. 
o The amount of cytoplasm is diminished, cell borders are poorly 
defined and there is increased nuclear cytoplasmic ratios. 
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Endocervical adenocarcinoma in situ 
 Friedell and McKay were the first to use the term adenocarcinoma- 
in-situ (AIS), to refer to the preinvasive lesions of cervical 
adenocarcinoma which failed to demonstrate  invasion. 
 Criteria 
o Cells occur in strips, sheets, rosettes and clusters with nuclei 
showing overlapping and crowding and the normal honeycomb 
pattern is lost.  
o Cells exhibit a feathering pattern with the cytoplasmic tags and 
nuclei protruding from the periphery with palisading nuclei. 
o Nuclei show oval to elongated shape and stratification with 
coarsely granular chromatin and inconspicuous nucleoli. 
o Nuclear/cytoplasmic ratios are increased; the quantity of cytoplasm 
and  mucin are reduced.  
o Background is generally clean (no tumor diathesis). 
HISTOPATHOLOGY: 
AIS refers to the presence of endocervical glands showing lining 
by columnar epithelial cells which demonstrate atypia but where there is 
no invasion. 
Nuclei are cigar-shaped and elongated and appear hyperchromatic 
with chromatin showing coarse granularity.  
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Intracellular mucin and cytoplasm are decreased resulting in an 
increased nuclear : cytoplasmic ratio.  
Two histological types were described by Ostor et al
35
: typical 
endocervical and intestinal type. 
Endocervical Adenocarcinoma  
 Cytologic criteria overlap those outlined for AIS, but with features of 
invasion. 
 Criteria 
o Cells are dispersed in singles, two or three dimensional sheets, or 
syncytial aggregates and clusters. 
o Nuclei are large and pleomorphic with irregular clumps of 
chromatin, irregular nuclear membrane some showing 
macronucleoli. 
o The background is necrotic showing tumor diathesis. 
HISTOPATHOLOGY: 
 Characterised by endocervical glands showing atypical columnar cell 
lining which are similar to the cells of AIS but demonstrate invasion. 
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ACOG (2009) Screening Guidelines
36
 
 Screening should begin at 21 years of age irrespective of onset of 
sexual activity. 
 Women who are more than 30 years in a monogamous 
relationship: Can be screened every 3 years when BOTH prior Pap 
smear and HPV testing for high risk types are negative. 
 Women who are more than 30 years with 3 consecutive negative 
Pap smears AND no risk factors: Can be screened every 3 years. 
 Annual screen or at more frequent intervals can be done if high-risk 
factors such as positive HIV status, history of DES exposure, prior 
history of cervical dysplasia, or cancer cervix.  
 Both liquid-based cytology and conventional Pap smear are 
acceptable for screening. 
 Routine screening may be discontinued in those with a history of 
total hysterectomy for benign indications and no prior dysplastic 
changes. 
ADVANTAGES OF PAP SMEAR 
 No injury to tissue is produced allowing frequent sampling to know 
the progress of the disease or regression of the lesion. 
 Smears cover a wider surface area than that sampled in a biopsy. 
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 Intimate cellular details are more often clearly seen in an isolated 
cell of the smear because of the minimum shrinkage and distortion 
in such cells. 
 Special stains can always be used as they are used in tissue 
sections. 
 Changes due to infection and irradiation are easily evaluated. 
LIMITATIONS OF PAP SMEAR 
 The interpretation of the morphological cellular changes is 
subjective. 
 The cytologic diagnosis is not always final. It must often be 
confirmed by histopathology. 
 The cytologist bases the diagnosis on the study of minute cellular           
details, while the histopathologist mainly examines the tissue 
pattern. 
 The interrelation and arrangement of the cells cannot be 
established. 
 The relation of the cells to the supporting stroma which is 
important in the diagnosis of an invasive carcinoma cannot be 
determined by cytology. 
 The size and the location of the lesion cannot be appreciated by 
cytology.  
 The exfoliated cells may not represent the true nature of the lesion. 
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 Poorly differentiated cells for example are the only cells exfoliating          
from a neoplasm with mixed components. 
 The screening of a smear can be time consuming and often the 
nature of the lesion is not obvious as in a histopathological section.  
LIQUID BASED CYTOLOGY: 
Though Pap smear had emerged as one of the efficient cancer 
screening programs that had been introduced, conventional Pap smear 
also had marked disadvantages which resulted in a higher number of false 
negatives
37. 
These limitations were mainly to two factors: errors in screening 
and errors in sampling/preparation. 
Moreover, it was obvious that the main hindrance to computerised 
imaging was the poor nature of the cytological preparation as is the case 
in conventional cytology. 
In order to improve increase the consistency and reliability of the 
Pap smear, LBC was designed to produce a sample that was fully 
representative of the material removed, and potentially easier to screen. 
THIN PREP and SUREPATH 
 These are the first attempted liquid based cytology methods, both 
of them being FDA approved. 
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 Clinical trials which were conducted with ThinPrep smears 
revealed an increase in disease detection
38,39
. 
 Colgan TJ et al40 studied the advantages of Surepath, another liquid 
based cytology in a cancer screening programme at Ontario. 
 The ThinPrep and the Surepath Pap tests brought about a 
breakthrough in Pap smear testing by increasing the number of 
adequate specimen and improving the disease detection rate. 
 Preparation of slides involves four steps: 
 
1. Collection of sample: 
 
This is done with a Cervex brush, the tip of which is broken and 
immersed into a preservative fluid which is ethanol based, hence 
preserving almost 100% of the sample collected and thereby avoiding any 
artefacts due to air drying. 
2. Process of cell enrichment 
 
Processing of samples is done in batches at the laboratory. The 
process of cell enrichment utilizes centrifugation and gravity dispersion 
in order to get rid of the blood, inflammation, mucus and other debris 
which may obscure the diagnostic material. 
3. Automated transfer of cells to slide 
The slide processor makes an uniformly dispersed preparation 
which contains an increased concentration of the representative cells. 
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These samples are then loaded onto the system thereby facilitating faster 
screening. 
4. Staining which is completely automated 
 
After formation of a thin uniform layer over the slide, the process 
is continued by the Slide Processor utilizing the Hematoxylin and EA/OG 
stains on-board. 
LIQUIPREP
TM
:  
 The first attempted liquid-based pap smear preparations utilized 
plastic devices, automated equipment, vacuums and filters. Hence, 
these methods were available at an increased cost per slide.  
 Maksem JA et al proposed an alternative method of LBC using a 
metastable alcoholic gel
41
.  
 Liqui-PrepTM which was put forward by the LGM International, 
USA) is considered to be a liquid-based pap smear of second 
generation. Its advantage lies in that the costlier instruments 
utilized for the first generation tests were not necessary, hence 
resulting in a method which is simpler to perform and available at a 
comparatively lower cost for screening of cervical cancer.  
STEPS IN PREPARATION OF LIQUIPREP
TM
 SLIDES: 
1.  Collection of sample with a Cervex brush, the tip of which is 
detached and put into a preservative fluid which is alcohol based.  
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2.  Cleaning solution added if necessary and centrifugation of the 
sample is done at 1000g for 10 minutes. 
3.  Addition of a proportional quantity of cell base reagent for 
resuspension, following which smears are made using the 
suspended sample in the form of a circle of 1.5 cm diameter. 
INTERPRETATION: 
The LP slides consisted of cells spread in a monolayer for a circle 
of about 1.5 cm diameter, thereby presenting enhanced clarity. 
Visualization is even more better because of considerably reduced blood 
and mucus but preserving the leukocytes and thereby a less obscuring 
effect
42
.  
MORPHOLOGY IN LBC SMEARS: 
Prompt fixation leads to good preservation resulting in clarity of 
chromatin. 
Cells appear slightly smaller due to rounding up effect of fixation 
in liquid. 
Clarity of nuclear features helpful in diagnosing dyskaryosis. 
Cells with low grade dyskaryosis (koilocytosis) are easily seen. 
Severe dyskaryosis often presents as dispersed single cells. 
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ADEQUACY: 
Bethesda- 5000 cells. 
INADEQUACY: 
 Before the laboratory: Cervix not fully visualised and sampled, vial 
broken and leaked or no brush in vial. 
 No endocervical cells: Cause of inadequacy in women treated for 
CGIN or CIN3 with endocervical margins involved. 
 Obscured by blood or polymorphs: Extremely rare occurrence on 
LBC 
 Contamination: Use of inappropriate lubricant 
 Inadequate cellularity: Thresholds not yet established 
ADVANTAGES OF LIQUIPREP TM 
 Settakorn J43 et al proposed that LiquipreqTM offers a considerably 
low cost compared to the first generation LBC. 
 Decreased chance of inadequacy of smear. 
 Smear less obscured by inflammatory cells and blood. 
 Clarity of nuclear chromatin. 
 Squamous cell abnormalities brought out better. 
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LIMITATIONS OF LIQUIPREP TM 
 Higher cost compared to conventional smear. 
 Experienced cytologist needed for interpretation. 
 Storage of vials may be problematic. 
 Diagnosis of glandular abnormalities decreased. 
AUTOMATION IN SCREENING  
 Since manual screening was tedious and habituating, automated 
screening methods were introduced. 
 Earlier methods were not consistently able to process conventional 
pap smears in view of the varying thickness and overlapping of 
nuclei. 
 Recent advances in liquid based cytology and the advent of more 
sophisticated algorithms have resulted in the dream of automated 
screening come true. 
PAPNET 
 It is a computer processing system driven by neural network used 
for screening conventional pap smears.  
 According to Mango,L.J. et al44,  this system relies on the ability of 
the human brain to learn rather than on rules and hence is sensitive 
in recognising a large number of patterns.  
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 The computer reviews and selects suspicious cells, that are 
displayed in 400x magnified fields and 128 video images, 
alongside the corresponding location on the grid for opinion of an 
experienced cytologist. 
 In a trial by Koss L.G. et al45 which involved the analysis of 9666 
negative pap smears which were manually reported as negative, 
Papnet was able to identify 464 (4.8%) abnormal smears. This 
constituted a 30% increased detection rate than the average 
detection rate of 12.7%.  
 The time taken for screening by Papnet was considerably reduced 
(approximately 3 vs. 10 minutes). 
AUTOPAP SYSTEM  
 An image processor is used to systematically scan the slide 
following which the images are run through a list of algorithms for 
interpretation and final impression.  
 Clinical trials by Wilbur,D.C.46 et al showed that when the 
Autopap system was used for rescreening, there was a five-fold 
improvement over manual screening. 
THIN PREP IMAGING SYSTEM: 
This system got the FDA approval in 2003.  The ThinPrep Imager 
scans the ThinPrep slide and picks up suspicious areas for further opinion 
of an experienced cytologist. 
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 A DNA stain stains the nuclei of the cervical cells present in the 
smear. Suspicious cells are those with high content of molecular 
DNA, and are enlarged with irregular shapes. The nuclei of these 
suspicious cells show more intense staining.  
 The ThinPrep Imaging System scans every smear and identifies 22 
fields of interest with respect to the DNA content of cells.  
 The cytologist reviews these 22 fields of interest and reports "no 
intraepithelial lesion" if all fields appear normal. If the 
cytotechnologist finds suspicious cells, then the entire slide is 
reviewed by a pathologist. 
BD FOCAL POINT
TM
 GS IMAGING SYSTEM: 
 The BD FocalPoint™ GS Imaging System is a computer-aided 
imaging instrument equipped with an automated microscope for 
initial screening for abnormal cells in cervical cytology samples. 
 This system scans the slide identifying up to 10 fields of interest 
which are viewed by the cytotechnologist using the review 
microscope. If there are no abnormal cells, the slide is considered 
negative but if abnormal cells are found, the whole slide is 
reviewed.  
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ADVANTAGES OF AUTOMATED IMAGING: 
 Helps reduce human error and thereby false negative test results. 
 Fivefold increased detection rates of abnormal cells. 
 Time taken for screening considerably reduced. 
DISADVANTAGES OF AUTOMATED SCREENING: 
 Early computer classification schemes were not able to deal with 
the numerous morphologies presenting as various degrees of 
abnormal findings. 
  Are not able to consistently process conventional pap smears owing 
to varying thickness and nuclear overlapping. 
HPV TESTING: 
 A definitive diagnosis can be made only by the direct detection of 
HPV DNA by in situ hybridization, by nucleic acid amplification 
via polymerase chain reaction (PCR), or by hybrid capture (HC) 
techniques.  
 Among the two, Hybrid capture is the more frequently used. It 
 utilises RNA probes that are complementary to the13 high-risk and 
 5 low-risk HPV types.  
 RNA-DNA hybrids are prepared by denaturing the HPV-DNA in 
 the specimen and hybridising to the RNA probes, which are then 
 captured on to microtiter plates containing monoclonal antibodies. 
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 Alkaline phosphatase conjugated second monoclonal antibody is 
 allowed to react with the captured hybrids and then a 
 chemoluminescent substrate is added.  
 The chemoluminescent substrate is cleaved by the alkaline 
 phosphatase conjugate and the light emitted is detected by a 
 luminometer. The intensity of light emitted is in proportion to the 
 amount of HPV-DNA. 
 This test can detect concentrations as low as 0.2pg/mL of  HPV 
 DNA in the sample .  
 The results from trials conducted by Hybrid Capture, Digene Corp. 
 which involved around 23, 000 women showed the sensitivity for  
 HPV testing was 90% for HSIL whereas it was only 67% for 
 conventional pap smear
47
. 
P16-INK4A: 
 P16-INK4A is a kinase inhibitor  which is cyclin-dependent and 
 shows overexpression in those cell lines in which the retinoblas-
 toma protein RB has been inactivated by E7 protein product of the 
 high risk HPV.  
 P16-INK4A can be identified by immunohistochemistry or ELISA, 
 and thus is a potential marker which can be used for screening for 
 cancer cervix. 
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 A study conducted in Italy involving 24,661 patients showed that 
 the sensitivity of P16-INK4A to diagnose HSIL was 88% and the 
 specificity was 61%
48
.  
CERVICAL BIOPSY 
 In this procedure cervical tissue is removed from the cervix to 
detect precursors of cancer or invasive cervical carcinoma. Cervical 
biopsies are of various types. In addition to removal of the cervical tissue 
for diagnosis, few biopsies may also excise completely the abnormal 
tissue and thereby used therapeutically for cancer precursors. 
Types of cervical biopsies: 
*Punch biopsy - This procedure removes a small bit of cervical tissue 
with the aid of a punch biopsy forceps. Various areas are sampled. 
*Cone biopsy or conization - A scalpel or LASER is used to excise a 
huge amount of cervical tissue in the shape of a cone from the cervix. 
*LLETZ  
 The gynaecologist uses electric current of varied power settings 
 passed via a wire loop to excise tissue from the cervix.  
 The cervical transformation zone along with the lesion are excised 
 to a depth of 8 mm, and extending 4-5 mm beyond the lesion.  
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 Low cost, high success rate, and ease of use are the advantages of 
 this procedure. 
 Complications of this procedure are infection, hemorrhage, damage 
 to the cervical stroma resulting in cervical stenosis or 
 incompetence. The LLETZ does not seem to affect fertility
49
.  
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MATERIALS AND METHODS 
This comparative analysis was a prospective study which was 
conducted at Institute of Social Obstetrics and Govt. Kasturba Gandhi 
hospital, Chennai, attached to Madras Medical College, from June 2011 
to June 2012. 
This study involved women [n=200] who attended the colposcopy 
out patient department, who were screened for cancer cervix using visual 
inspection with acetic acid and Lugol‟s iodine, conventional Pap smear 
cytology and liquid based cytology. 
INCLUSION CRITERIA: 
1.  Women attending the colposcopy out patient department with 
 symptoms of white discharge per vagina, abnormal uterine 
 bleeding, postcoital bleeding, pruritis vulva and those with family 
 history of gynaecological malignancy.  
2.  Women who are sexually active or on oral contraceptives. 
3.  Non pregnant women. 
4.  Both nullipara and multipara. 
EXCLUSION CRITERIA: 
1.  Pregnant women. 
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2.  Menstruating women. 
3.  History of hysterectomy. 
4.  Sexual intercourse with spermicidal jelly, douches/tampons 24 
 hours prior to pap smear examination. 
VISUAL INSPECTION WITH ACETIC ACID (VIA) & WITH 
LUGOL’S IODINE (VILI) 
THE EXAMINATION: 
 The procedure is carefully explained to the patients, they are made 
comfortable and privacy ensured. 
 The patient is placed in the lithotomy position. 
 Good visualization ensured. 
 Any abnormal findings in the external genitalia are recorded. 
  Cusco‟s speculum is inserted into the vagina so that the cervix is 
clearly visualised. 
 The discharge or mucus is wiped by means of a cotton swab wet 
with normal saline. 
 The external appearance of cervix is recorded. 
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 Cervix washed using freshly prepared 5% acetic acid using a 
syringe.  (Alternatively can be applied with cotton swab). 
 The cervix observed for acetowhite areas after waiting for a 
minute. 
 Lugol‟s Iodine applied by means of a cotton swab or syringe. 
 The cervix inspected for iodine uptake areas & non uptake areas. 
  Findings were recorded. 
CHARATERSTICS OF VIA / VILI –POSITIVE CASES 
(A)Low grade lesion 
Detection of any acetowhite area – VIA 
Detection of any non iodine uptake areas – VILI. 
 
(B) High Grade Lesion 
Presence of opaque acetowhite patches which appear well 
circumscribed,  abutting the squamocolumnar junction. 
Detection of thick, dense, saffron yellow or mustard yellow iodine 
non-uptake lesions in the tranformation zone around the squamocolumnar 
juction. 
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CONVENTIONAL PAP SMEAR 
Timing: 
 Smears are not collected during the menstrual periods. 
 The patient should not have intravaginal medications / douches 48 
 hrs before the test. 
 Patient should not have intercourse the previous night. 
Precautions: 
 Lubricants of all types avoided. 
 Vaginal examination to be done only after taking smear. 
Method: 
 Combination of Ayre‟s Spatula and Endocervical brush has proved 
 to give better results. 
 The patient is put in lithotomy position. 
 Visualisation of cervix by Cusco‟s speculum. 
 The spatula placed at the level of cervical os and rotated through 
 360° circle around the os ensuring that the spatula is in contact 
 with the ectocervix.  
 Optimal sample is taken and a smear is made on a clean slide. 
  Endocervical brush is inserted into the os and rotated through 
 180°.  
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 The angle of rotation should be parallel to the endocervical canal. 
 The sample is rolled on to the slide in the direction opposite to 
 which it was rolled for collecting the sample. 
 The smear quality is better if the spatula is used first following 
 which endocervical brush is used thereby making obscuring of 
 smears by blood less likely. 
 The slide is fixed with 95% ethyl alcohol – Fixative. 
STEPS IN PREPARATION OF LIQUIPREPTM SLIDES: 
Collection of sample: The sample was taken with the help of a 
Rover Cervex brush, the tip of which was broken and dropped into the 
alcohol based LP preservative fluid. 
Concentration of the sample: The vial along with the tip of the 
brush was shaken forcefully with the help of a vortex for about 10 
seconds. The contents of the vial were emptied into a 15 ml centrifuge 
tube. Samples that contained mucus or blood were cleared with 4 ml of 
cleaning solution. Centrifugation was done for approximately1000g for 
10 minutes. 
Preparation of the slides: The supernatant present following 
centrifugation was poured off. Cell base reagent was added to the sample 
in an amount proportional to the cell pellet formed, in accordance to the 
instructions by the manufacturer. A vortex was used for 10 seconds to 
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resuspend the cell pellet. Then about 50 microlitres of the suspended cell 
pellet was pipetted onto a clean slide in the form of a circle of 1.5 cm 
diameter following which the slides are air-dried and stained by routine 
Pap stain. 
PAP STANING: 
MATERIALS REQUIRED: 
 Harris hematoxylin was prepared using potassium alum and 
 mercuric oxide and filtered into a dark bottle for storage. The 
 working solution was replaced every 1 to 3 weeks, depending on 
 the number of slides being stained. 
 OG 6 
                   Orange G 1.0% solution in 95% Alcohol - 100ml. 
                   Phosphotungstic acid - 0.015gm. 
 EA 36 
                   Light green SF yellowish - 0.14% in 95% alcohol - 45ml. 
                   Bismark brown Y- 0.5% in 95% Alcohol - 10ml. 
                   Eosin yellow - 0.55% in 95% alcohol - 45ml. 
                   Phosphotungstic acid - 0.2 gm. 
                   Lithium carbonate, saturated aqueous solution - 1 drop. 
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PROCEDURE 
1. Slides were transferred directly from the fixative, without 
drying, to 95% alcohol, and brought down through 70 and 50% 
alcohols to distilled water. 
2. Slides were stained in Harris hematoxylin for 5 minutes. 
3. Gently rinsed briefly in distilled water. 
4. They were dipped in 0.25%Hcl in 50% ethanol (acid alcohol) 
about six times for 20 seconds. 
5.  Placed in running tap water for 6 minutes. 
6. They were rinsed in distilled water and run through 70%, 80% 
to 95% alcohol. 
7. And stained in OG 6 for 3 minutes. 
8. The slides are then rinsed in 95% alcohol- 2 changes. 
9. Stained in EA 36 for 3 minutes. 
10. Rinsed in 95% alcohol- 3changes. 
11. Dehydrated in absolute alcohol, followed by equal parts of 
absolute alcohol and xylol, cleared in xylol and mounted. The 
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smears were analyzed and the cellular details were evaluated 
under a light microscope.  
PAP REPORTING IN THE HOSPITAL 
1. Negative for SIL 
2. Cervicitis 
3. Atypical cells of undetermined significance 
4. Atypical cells cannot exclude HSIL  
5. Low grade SIL 
6. High grade SIL 
7. Invasive carcinoma 
 
CERVICAL BIOPSY 
For 77 cases (65 cases which showed abnormal results on either 
VIA/VILI or pap smear and 12 normal cases), either punch biopsy or 
LLETZ biopsy was taken and sent for histopathological report. The 
biopsy reporting in our hospital is as follows. 
1. No major lesion detected 
2. Cervicitis 
3. Mild Dysplasia-CIN 1 
4. Moderate dysplasia-CIN 2 
5. Severe dysplasia-CIN 3,  
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6. Carcinoma in situ 
7. Invasive Carcinoma 
COMPARATIVE ANALYSIS: 
The information collected regarding all the selected cases were 
recorded in a Master Chart. 
Sensitivity, specificity, accuracy, positive predictive value and 
negative predictive values, percentage of false positives and false 
negatives were calculated using the following formulae and taking HPE 
findings as the Gold standard. 
Sensitivity =              True positive                   x 100 
                            True positive + false negative 
Specificity =                   True negative                x 100 
                              False positive + true negative 
Positive predictive value =              True positive                x 100 
                                               True positive + False positive 
Negative predictive value =               True negative                  x 100 
                                                    True negative + False negative 
Percentage of false positives =            False positive            x 100 
                                                      False positive + True negative 
Percentage of false negatives =            False negative                x100 
                                                       False negative + True positive 
  
 
 
 
 
OBSERVATION 
AND 
RESULTS
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OBSERVATION AND RESULTS 
The study was conducted at Institute of Social Obstetrics and Govt. 
Kasturba Gandhi Hospital for Women & Children, Chennai, attached to 
Madras Medical College during the period June 2011 – June 2012. 
200 Patients were included in the study group and the outcome 
analysed using various parameters. The results were subjected to 
statistical analysis. 
 Sample size – 200. 
 Visual Inspection with Acetic Acid (VIA), done in all 200 patients. 
 Visual Inspection with Lugol‟s Iodine (VILI) done in all 200 
patients . 
 Conventional Pap smear cytology and liquid based cytology was 
done in all 200 cases. 
 Those cases showing VIA/VILI Positive (or) cytology positive 
were subjected to cervical biopsy. 
 For 12 cases which were negative on Pap smear and also on 
VIA/VILI, biopsy was done (as control) 
I. CHARACTERISTICS OF THE STUDY GROUP: 
70 patients (35%) enrolled in the study belonged to the age group 
of 31-40 years (Table 1 and Chart 1). 
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TABLE 1 
AGE DISTRIBUTION 
n=200 
AGE (YEARS) ≤20 21-30 31-40 41-50 ≥51 
FREQUENCY 2 39 70 60 29 
PERCENT 1% 19.5% 35% 30% 14.5% 
 
37% of the patients were of socioeconomic grade 4 while 33.5% of 
the patients were of socioeconomic group 5 (Table 2 and Chart 2). 
TABLE  2 
 DISTRIBUTION OF SOCIOECONOMIC GROUP IN THE 
STUDY GROUP 
     n=200 
GRADE 2 3 4 5 
FREQUENCY 12 47 74 67 
PERCENT 6% 23.5% 37% 33.5% 
 
Among the study group, 82% of the patients attained menarche at 
13-14 years of age (Table 3 and Chart 3). 
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TABLE 3 
DISTRIBUTION OF AGE AT MENARCHE  
IN THE STUDY GROUP 
       n=200 
AGE (YEARS) ≤12 13-14 15-16 
FREQUENCY 26 164 10 
PERCENT 13% 82% 5% 
 
Among the 200 patients, 73% of the marriages in the study group 
were around 15-20 years (Table 4). 
TABLE 4 
DISTRIBUTION OF AGE AT MARRIAGE  
IN THE STUDY GROUP 
      n=200 
AGE (YEARS) 15-20 21-25 26-30 ≥31 
FREQUENCY 146 46 4 4 
PERCENT 73% 23% 2% 2% 
 
Out of the 200 patients, 93 patients (46.5%) in this study group 
were of parity 2 and 57 patients (28.5%) were of parity 3(Table 5 and 
Chart 4).     
 
56 
 
TABLE 5 
 
DISTRIBUTION OF STUDY GROUP  
ACCORDING TO PARITY 
   n=200 
PARITY 0 1 2 3 ≥4 
FREQUENCY 6 18 93 57 26 
PERCENT 3% 9% 46.5% 28.5% 13% 
 
The most common presenting symptom in the study group was 
white discharge per vaginum (63%) followed by abnormal uterine 
bleeding (19.5%) (Table 6 and Chart 5). White discharge per vagina was 
also the commonest presenting symptom in patient who showed dysplasia 
on biopsy. 
TABLE 6 
DISTRIBUTION OF SYMPTOMS AMONG  
THE STUDY GROUP 
      n=200 
SYMPTOMS FREQUENCY PERCENT 
WHITE DISCHARGE 126 63% 
AUB 39 19.5% 
POSTCOITAL BLEED 4 2% 
PAIN ABDOMEN 24 12% 
PRURITIS VULVA 7 3.5% 
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RESULTS OBTAINED BY SCREENING METHODS 
FINDINGS IN VIA/VILI 
VIA/VILI was positive in 68 cases (34%) and 132 cases (66%) 
showed negative results (Table 7 and Chart 6). 
TABLE 7 
DISTRIBUTION OF VIA/VILI POSITIVE CASES IN THE  
STUDY GROUP 
VIA/VILI POSITIVE 68 CASES 34% 
VIA/VILI NEGATIVE 132 CASES 66% 
 
In the study group majority of the patients who were VIA/VILI 
positive belonged to 31-40 years age group (39.7%) and 41-50 years 
(27.9%) –(Table 8 and Chart 7) 
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TABLE 8 
AGEWISE DISTRIBUTION OF VIA/VILI POSITIVE CASES 
    n=68 VIA/VILI positive cases 
AGE 21-30 31-40 41-50 ≥51 
VIA/VILI POSITIVE 8 27 19 14 
PERCENT 11.8% 39.7% 27.9% 20.6% 
 
36.8% of the patients who were VIA/VILI positive were of 
socioeconomic grade 4 and 30.8% of the patients were of grade 5 (Table 
9 and Chart 8). 
TABLE 9 
 VIA/VILI RESULTS- SOCIOECONOMIC STATUSWISE 
    n=68 VIA/VILI positive cases 
SOCIOECONOMIC 
STATUS 
2 3 4 5 
FREQUENCY 5 17 25 21 
PERCENT 7.4% 25% 36.8% 30.8% 
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CYTOLOGY REPORTS 
Pap smear report was inadequate in 7 patients (3.5%), normal in 20 
patients (10%), atrophic smear in 8 patients (4%), Cervicitis in 115 
patients (57.5%), ASCUS in 2 patients (1%), LSIL in 11 patients (5.5%), 
HSIL in 18% (9%), SCC in 17 patients (8.5%) and adenocarcinoma in 2 
patients (1% )– (Table 10 and Chart 9). 
TABLE 10 
CONVENTIONAL PAP SMEAR RESULTS 
FINDINGS NUMBER OF 
CASES 
PERCENT 
INADEQUATE 7 3.5% 
NORMAL 20 10% 
ATROPHIC 8 4% 
CERVICITIS 115 57.5% 
ASCUS 2 1% 
LSIL 11 5.5% 
HSIL 18 9% 
SCC 17 8.5% 
ADENOCARCINOMA 2 1% 
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LBC report was inadequate in 3 patients (1.5%), normal in 20 
patients (10%), atrophic smear in 9 patients (4.5%), Cervicitis in 113 
patients (56.5%), LSIL in 15 patients (7.5%), HSIL in 21% (10.5%), SCC 
in 17 patients (8.5%) and adenocarcinoma in 2 patients (1%)– (Table 11 
and Chart 10). 
TABLE 11 
LBC RESULTS 
FINDINGS NUMBER OF 
CASES 
PERCENT 
INADEQUATE 3 1.5% 
NORMAL 20 10% 
ATROPHIC 9 4.5% 
CERVICITIS 113 56.5% 
ASCUS - 0% 
LSIL 15 7.5% 
HSIL 21 10.5% 
SCC 17 8.5% 
ADENOCARCINOMA 2 1% 
 
Biopsy was reported as cervicitis in 22 cases (28.5%), CIN 1 in 16 
cases (20.8%), CIN 2 in 14 cases (18.2%), CIN 3 in 6 cases (7.8%), 
carcinoma in situ with focal microinvasion in 1 case (1.3%), SCC in 16 
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cases (20.8%) and adenocarcinoma in 2 cases (2.6%)– (Table 12 and 
Chart 11). 
TABLE 12 
BIOPSY FINDINGS 
 Biopsy done in 77 cases. 
 65 cases either VIA/VILI or cytology positive. 
 12 cases VIA/VILI negative and also negative on both 
conventional pap and LBC. 
 
FINDINGS NUMBER OF 
CASES 
PERCENT 
CERVICITIS 22 28.5% 
CIN 1 16 20.8% 
CIN 2 14 18.2% 
CIN3  6 7.8% 
CIS 1 1.3% 
SCC 16 20.8% 
ADENOCARCINOMA 2 2.6% 
 
The most common age group of CIN is 31-40 years whereas 
invasive carcinoma is common above the age group of 50 years (Table 13 
and Chart 12). 
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TABLE 13 
AGEWISE DISTRIBUTION OF BIOPSY RESULTS 
BIOPSY RESULTS ≤20 21-30 31-40 41-50 ≥50 
CERVICITIS(22) - 1 11 6 4 
CIN 1(16) - 2 7 5 2 
CIN 2(14) - 2 7 5 - 
CIN 3(6) - - 5 1 - 
CIS(1) - - - - 1 
SCC(16) - - 2 3 11 
ADENOCARCINOMA(2) - - 1 - 1 
 
COMPARISON STUDIES 
28 low grade lesions on colposcopy were reported as normal- 1, 
inflammatory- 16, ASCUS- 2, LSIL- 8 and HSIL-1. 21 high grade lesions 
on colpocopy were reported as inflammatory- 1, inadequate- 3 and HSIL- 
17. 19 cases of invasive carcinoma turned out to be 17 cases of SCC and 
2 cases of adenocarcinoma. 132 negative cases on colposcopy were 
normal- 19, atrophic- 8,inflammatory- 98, inadequate-4 and LSIL- 3 on 
pap smear (Table 14 and Chart 13). 
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TABLE 14 
VIA/VILI WITH CONVENTIONAL PAP 
 
VIA/VILI 
CONVENTIONAL PAP SMEAR 
NOR ATROP CERVI
CITIS 
INADEQ ASCUS LSIL HSIL SCC ADENOCA 
LOW 
GRADE 
(28)  
1  16  2 8 1   
HIGH 
GRADE 
(21) 
  1 3   17   
INVASIVE 
CA (19) 
       17 2 
NEGATIVE 
(132) 
19 8 98 4  3    
 
28 low grade lesions were reported as normal-1, inflammatory- 16, 
LSIL- 10 and HSIL- 1. 21 high grade lesions were reported as 
inflammatory-1 and HSIL- 20. 19 cases of invasive carcinoma were SCC-
17 and adenocarcinoma- 2. 132 negative lesions were reported as normal- 
19, atrophic- 9, inflammatory- 96, inadequate- 3 and LSIL-5 (Table 15 
and Chart 14).  
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TABLE 15 
VIA/VILI WITH LBC 
 
VIA/VILI 
LIQUID BASED CYTOLOGY 
NOR ATROP CERVI 
CITIS 
INADEQ ASCUS LSIL HSIL SCC ADENO
CA 
LOW 
GRADE 
(28) 
1  16   10 1   
HIGH 
GRADE 
(21)  
  1    20   
INVASIVE 
CA(19) 
       17 2 
NEGATIVE
(132) 
19 9 96 3  5    
 
20 low grade lesions were reported as cervicitis- 8, CIN I-10 and 
CIN II- 2. 21 high grade lesions on colposcopy were reported as CIN I- 3, 
CIN II-12 and CIN III- 6. 17 cases of invasive carcinomas were reported 
as carcinoma in situ with focal microinvasion- 1, SCC- 16 and 
adenocarcinoma- 2 on biopsy (Table 16and Chart 15). 
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TABLE 16 
VIA/VILI WITH BIOPSY 
 
VIA/VILI 
BIOPSY 
CERVICITIS CIN 1 CIN2 CIN 3 CIS SCC ADENOCA 
LOW GRADE(20) 8 10 2     
HIGH GRADE(21)  3 12 6    
INV CA(19)     1 16 2 
NEGATIVE(17) 14 3      
 
True positive cases- 52  
True negative cases- 14 
False positive- 8 
False negative- 3 
TABLE 17 
NUMBER OF TRUE POSITIVES, TRUE NEGATIVES, FALSE 
POSITIVES AND FALSE NEGATIVES ON VIA/VILI 
 
VIA/VILI 
BIOPSY 
Positive Negative 
Positive 52 8 
Negative 3 14 
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Sensitivity=52/55x100=94.55% 
Specificity=14/22x100=63.64% 
Positive predictive value=52/60x100=86.67% 
Negative predictive value=14/17x100=82.35% 
Percentage of false positives=8/22x100=36.36% 
Percentage of false negatives=3/55x100=5.45% 
 
1 normal smear was reported as cervicitis on biopsy, 22 cases of 
cervicitis on pap smear were given as cervicitis- 19 and CIN I- 3 on 
biopsy. 1 atrophic smear was reported as cervicitis. 3 inadequate smears 
were reported as CIN II- 2 and CIN III- 1. 2 cases of ASCUS were CIN I 
on biopsy. 11 cases of LSIL were given as CIN I-10 and cervicitis- 1. 18 
cases of HSIL turned out to be CIN I- 2, CIN II-11, CIN III-5. 19 cases of 
invasive carcinoma were reported carcinoma in situ with focal 
microinvasion- 1, SCC- 16 and adenocarcinoma- 2 on biopsy (Table 18 
and Chart 16). 
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TABLE 18 
CONVENTIONAL PAP WITH BIOPSY 
 
CONVENTIONAL 
PAP SMEAR 
BIOPSY 
CIN 
1 
CIN 
2 
CIN 
3 
CIS SCC ADENO
CA 
CERVICITIS 
NORMAL(1)       1 
CERVICITIS(22) 3      19 
ATROPHIC(1)       1 
INADEQ(3)  2 1     
ASCUS(2) 2       
LSIL(11) 10      1 
HSIL(18) 2 11 5     
INV CA(19)    1 16 2  
 
True positives- 49 
True negatives- 21 
False positive- 1 
False negative- 6 
TABLE 19 
NUMBER OF TRUE POSITIVES, TRUE NEGATIVES, FALSE 
POSITIVES AND FALSE NEGATIVES ON CONVENTIONAL 
PAP SMEAR 
CONVENTIONAL 
PAP SMEAR 
BIOPSY 
Positive Negative 
Positive 49 1 
Negative 6 21 
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Sensitivity=49/55x100=89.09% 
Specificity=21/22x100=95.45% 
Positive predictive value=49/50x100=98% 
Negative predictive value=21/27x100=77.78% 
Percentage of false positives=4.55% 
Percentage of false negatives=10.91% 
2 normal smears were reported as cervicitis on biopsy,15 cases of 
cervicitis on LBC smear were given as cervicitis- 12 and CIN I- 3 on 
biopsy. 2 atrophic smears were reported as cervicitis. 15 cases of LSIL 
were given as CIN I-11, CIN II- 1 and cervicitis-3. 21 cases of HSIL 
turned out to be CIN I- 2, CIN II-13, CIN III-6. 19 cases of invasive 
carcinoma were reported as carcinoma in situ with focal microinvasion-1, 
SCC-16 and adenocarcinoma-2 on biopsy(Table 20 and Chart 17). 
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TABLE 20 
 LBC WITH BIOPSY 
 
LIQUIPREP TM 
BIOPSY 
CIN 1 CIN 2 CIN 3 CIS SCC ADENOCA CERVICITIS 
NORMAL(2)       2 
CERVICITIS(15) 3      12 
ATROPHIC(2)       2 
INADEQ(0)        
ASCUS(0)        
LSIL(15) 11 1     3 
HSIL(21) 2 13 6     
INV CA(19)    1 16 2  
 
True positives- 52 
True negatives- 19 
False positives- 3 
False Negatives- 3 
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TABLE 21 
NUMBER OF TRUE POSITIVES, TRUE NEGATIVES,   FALSE 
POSITIVES AND FALSE NEGATIVES ON LIQUIPREP TM 
 
LIQUID BASED CYTOLOGY 
BIOPSY 
Positive Negative 
Positive 52 3 
Negative 3 19 
 
Sensitivity=52/55x100=94.55% 
Specificity=19/22x100=86.36% 
Positive predictive value=52/55x100=94.55% 
Negative predictive value=19/22x100=86.36% 
Percentage of false positives=13.63% 
Percentage of false negatives=5.45% 
 
20 normal smears were reported as normal- 13, cervicitis- 6 and 
inadequate- 1 on liquid based cytology. 115 inflammatory smears were 
given as normal-6 cervicitis- 104, inadequate- 1, atrophic- 1 and LSIL- 
3.8 atrophic smears were reported as inadequate- 1 and atrophic- 7. 7 
inadequate smears were reported as normal- 1, cervicitis- 2, atrophic- 1 
and HSIL- 3. 2 cases of ASCUS were given as cervicitis- 1 and LSIL- 
1.11 cases of LSIL and 18 cases of HSIL were concordant on both 
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conventional Pap and LBC. 17 cases of SCC and 2 cases of 
adenocarcinoma were reported the same in LBC too (Table 22 and Chart 
18).   
TABLE 22 
CONVENTIONAL PAP WITH LBC 
CONVENTIO
NAL PAP 
LIQUIPREP TM 
NORMAL CERVICI
TIS 
INADEQU
ATE 
ATROP
HIC 
LSIL HSIL SCC ADENOCA 
NORMAL(20) 13 6 1      
CERVICITIS 
(115)  
6 104 1 1 3    
ATROPHIC(8)   1 7     
INADEQ(7) 1 2  1  3   
ASCUS(2)  1   1    
LSIL(11)     11    
HSIL(18)      18   
SCC(17)       17  
ADENOCA(2)        2 
 
  The percentage of concordance of conventional pap smear with 
 biopsy was 100% for ASCUS, 90.91% for LSIL, 88.89% for HSIL 
 and 100% for invasive carcinoma (Table 23). 
 The percentage of concordance of Liquiprep TM pap smear with 
 biopsy was 80% for LSIL, 90.47% for HSIL and 100% for invasive 
 carcinoma (Table 23). 
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TABLE 23 
PERCENTAGE OF CONCORDANT CASES IN  
CONVENTIONAL PAP AND LIQUIREP TM 
 
 
 
ASCUS LSIL HSIL INVASIVE 
CARCINOMA 
CONVENTIONAL 
PAP 
    
TOTAL 2 11 18 19 
CONCORDANT 2 10 16 19 
%OFAGREEMENT 100% 90.91% 88.89% 100% 
LIQUIPREP TM     
TOTAL - 15 21 19 
CONCORDANT - 12 19 19 
%OFAGREEMENT - 80% 90.47% 100% 
 
Both VIA/VILI and LBC had similar sensitivity rates in the 
screening of cancer cervix compared to conventional Pap smear. 
However the specificity and PPV were highest for the conventional Pap 
smear followed by LBC. Liquiprep TM had the highest negative 
predictive value (Table 24 and Chart 19 & 20). 
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TABLE 24 
EFFICACY OF VARIOUS SCREENING PROCEDURES 
 
 
 
VIA/VILI CONVENTIONAL 
PAP 
LIQUIPREP 
TM 
SENSITIVITY 94.55% 89.09% 94.55% 
SPECIFICITY 63.64% 95.45% 86.36% 
PPV 86.67% 98% 94.55% 
NPV 82.35% 77.78% 86.36% 
PERCENTAGE O F 
FALSE 
POSITIVES 
36.36% 4.55% 13.63% 
PERCENTAGE OF 
FALSE 
NEGATIVES 
5.45% 10.91% 5.45% 
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ECTOPY OF CERVIX 
      
 
 
 
 
FIGURE 1: VIA- Normal cervix FIGURE 2: VILI- Normal cervix 
FIGURE 4: VILI- Ectopy of cervix FIGURE 3: VIA- Ectopy of cervix 
  
SATELLITE LESION 
      
 
 
 
 
LEOPARD SKIN APPEARANCE 
      
 
 
 
 
FIGURE 5: VIA- Satellite lesion FIGURE 6: VILI- Satellite lesion 
 
FIGURE 7: VIA- Leopard skin 
spots 
FIGURE 8: VIA- Leopard skin 
spots 
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LOW GRADE LESION 
      
 
 
 
FIGURE 9: VIA- endocervical 
polyp 
FIGURE 10: VILI- endocervical 
polyp 
 
FIGURE 11: VIA- Low grade 
lesion 
 
 
FIGURE 12: VILI- Low grade 
lesion 
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INVASIVE CARCINOMA 
      
 
 
 
 
FIGURE 13: VIA- High grade 
lesion 
FIGURE 14: VIA- High grade 
lesion 
 
FIGURE 15: VIA- Invasive 
carcinoma 
FIGURE 16: VIA- Invasive 
carcinoma 
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INFLAMMATORY SMEAR 
         
 
 
 
FIGURE 17: Conventional Pap- 
Normal smear (10X) 
FIGURE 18: LiquiPrep TM- 
Normal smear (10X) 
 
FIGURE 19: Conventional Pap- 
Inflammatory smear (10X) 
                               smear 
FIGURE 20: LiquiPrep TM- 
Cervicitis (10X) 
  
 
INFECTIONS 
       
 
 
  
 
ATROPHIC SMEAR 
      
 
 
FIGURE 21: Conventional Pap- 
Trichomonas vaginalis (40X) 
                               vaginalis 
FIGURE 22: Conventional Pap- 
Candida albicans (40X) 
                               albicans 
FIGURE 23: Conventional Pap- 
Atrophic smear (10X) 
FIGURE 24: LiquiPrep TM- 
Atrophic smear (10X) 
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LOWGRADE SQUAMOUS INTRAEPITHELIAL LESION 
      
 
 
FIGURE 25: Conventional Pap- 
ASCUS (40X) 
FIGURE 26: Conventional Pap- 
ASCUS showing binucleate cell 
(40X) 
FIGURE 27: Conventional Pap- 
LSIL (40X) 
FIGURE 28: LiquiPrep TM- LSIL 
(40X) 
 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION 
    
 
 
 
 
 
 
 
 
 
 
 
 
INVASIVE SQUAMOUS CELL CARCINOMA 
. 
    
 
 
 
 
 
 
 
 
 
 
FIGURE 29: Conventional Pap- 
HSIL (40X) 
FIGURE 30: LiquiPrep TM- HSIL 
(40X) 
 
FIGURE 31: Conventional Pap- 
Invasive squamous cell carcinoma 
(40X) 
 
FIGURE 32: LiquiPrep TM- 
Invasive squamous cell carcinoma 
(40X) 
FIGURE 30: LiquiPrep TM- HSIL 
(40X) 
 
FIGURE 32: LiquiPrep TM- 
Invasive squamous cell carcinoma 
(40X) 
 INVASIVE ADENOCARCINOMA 
      
 
 
 
 
 
CHRONIC CERVICITIS     
      
 
 
                                                 
 
FIGURE 33: Conventional Pap- 
Invasive Adenocarcinoma cervix 
(40X) 
FIGURE 34: LiquiPrep TM- 
Invasive Adenocarcinoma cervix 
(40X) 
 
FIGURE 35: HPE- Chronic 
cervicitis (10X) 
FIGURE 36: HPE- Papillary 
endocervicitis (10X) 
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FIGURE 37: HPE- CIN I (10X) FIGURE 38: HPE- CIN II (10X) 
FIGURE 39: HPE- CIN III (10X) FIGURE 40: HPE- Carcinoma in 
situ (10X) 
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FIGURE 41: HPE- Well 
differentiated squamous cell 
carcinoma (10X) 
 
FIGURE 42: HPE- Moderately 
differentiated squamous cell 
carcinoma (10X) 
FIGURE 43: HPE-Poorly 
differentiated squamous cell 
carcinoma (10X) 
 
FIGURE 44: HPE- Moderately 
differentiated adenocarcinoma 
(10X) 
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DISCUSSION 
This prospective comparative study analyses the efficacy of visual 
inspection methods (VIA/VILI), conventional cytology and liquid based 
cytology with biopsy as gold standard as an easily interpretable low cost 
but effective method for cancer cervix. 
1. CHARACTERISTICS OF STUDY GROUP 
 AGE: 
 In this study most of the patients were in the age group 31 to 
40 years (35%). 
 In the cross sectional study done in October 1995 to August 
1997women attending 15 primary health center in 
Zimbabwe
51
 to study the efficacy of VIA and cytology in the 
study group, the  age group included was 25 to 55 years and 
the mean age was 33.25.  
 In British Columbia study 1990, the age group of 15 to 18 
were 27%, 20 to 34 were 68%, 35 to 59 were 46% and 60 
and above were 21% with highest age incidence noted in 
third and fourth decade
52
. 
 In a study evaluating the efficacy of VIA with conventional 
pap smear by Divya Hedge et al
53
, 56.6% belonged to the 
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41-50 year age group and 68.5% belonged to the lower 
middle age group.  
 In a study by SO Albert et al54 comparing VIA and pap 
smear the patients were aged between 14 and 45 years with a 
mean of 28.7 ± 4.2 years.  
 A study conducted in AIIMS, New Delhi in 200355 to 
evaluate and compare test performance of visual inspection 
of cervix by a doctor and paramedical worker, included 
study group of patients with 64% belonging to 30-39 years.  
 In a study comparing the colposcopic and cytologic findings 
by Maziah AM et al
56
, 70% of the patients were between 30-
49 years of age.  
 Shalini et al58 showed that 32 year was the mean age of 
patients with  benign pathology in their study. Dysplasia was 
found to be more common between 20 and 39 years. 
 Kushtagi and Fernandes in their study showed the 
prevalence of dysplasia was higher in women over 30 
years
59
. 
DISTRIBUTION OF SOCIOECONOMIC STATUS IN THE 
STUDY GROUP: 
 In this study most of the patients were in the socioeconomic group 
 4(37%) and group 5(33.5%). 
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 In the cross sectional screening test done in Zimbabwe51 comparing 
 the efficacy of VIA and cytology in the study group, most of the 
 patients were belonging to socioeconomic status 3. 
 In a study conducted in Institute of medical sciences, Lahore in 
 2007
57
showed that all women with CIN belonged to low socio 
 economic status and about 24-80% belonged to very low socio 
 economic status of income between Rs.3000- 5000/month. 
DISTRIBUTION OF AGE AT MENARCHE AND AGE AT 
MARRIAGE  IN THE STUDY GROUP: 
 In this study most of the patients attained menarche at 13-14 yrs 
 (82%) and 73% of them got married at 15-20 yrs. 
 In the cross sectional screening test done in 15 primary health 
 center in Zimbabwe
51
, 56% attained menarche at 13 years and most 
 of them got married at 18 years (46%). 
 In a study comparing the colposcopic and cytologic findings by 
 Maziah AM et al
56
, 44% of the patients were below 19 years of age 
 at first coitus and another 50% from 20-29 years of age. 
 A study conducted in AIIMS, New Delhi in 200355 showed that the 
 mean age at first sexual intercourse was 19+/- 3.3 years. 
DISTRIBUTION OF PARITY AMONG THE STUDY GROUP: 
 In this study 46.5% of patients were of parity 2. 
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 In a study by SO Albert et al54 comparing VIA and Pap smear , 
 79.8% patients  were multiparous, while 20.2%  were 
 grandmultiparous. 
 In a study comparing the colposcopic and cytologic findings by 
 Maziah AM et al
56
, 92% of the patients were multiparous.  
DISTRIBUTION OF SYMPTOMS IN THE STUDY GROUP: 
 The most common presenting symptom in the study group (63%) 
 was white discharge per vagina. The common presenting symptom 
 in women with dysplasia was also white discharge per vagina.  
 In a study evaluating the efficacy of VIA with conventional pap 
 smear by Divya Hedge et al
53
, the major presenting complaint was 
 menstrual irregularities in 40.8% women. 12.9% of women had 
 complaints of white discharge per vagina. White discharge per 
 vagina was the most common presenting complaint among patients 
 in whom precancerous and malignant lesions were detected. 
2. VISUAL INSPECTION FINDINGS-VIA AND VILI 
 All patients were subjected to colposcopy and visual inspection 
 with acetic acid and Lugol‟s iodine.  
 VIA and VILI positive in 68 cases and in 132 cases the test results 
 were negative. Thus 34% of the screening population showed 
 positive results. 
78 
 
 The above findings correlated with the study conducted by 
 Sankaranarayanan et al
60
, in Kolkatta involving 5881 women 
 which showed VIA positive results in 30% .  
 Cecchini S et al reported positive VIA in 25.4% in their study61. 
AGEWISE DISTRIBUTION OF VIA/VILI POSITIVE CASES 
 In this study, 39.7% of the VIA/VILI positive cases were in the age 
 group of 31-40 years.  
 This was similar to the study conducted by Maziah AM56 et al at 
 Universiti Kebangsaan Malaysia, Kuala Lumpur in which 36% of 
 preclinical cervical cancer were in the age group of 30-39 years. 
VIA/VILI RESULTS- SOCIOECONOMIC STATUSWISE 
 In this study majority of VIA/VILI positive cases were of 
 socioeconomic class 4 (36.8%) and 5 (30.8%). 
 In a study at Institute of Medical sciences Lahore, involving 500 
 patients, low socioeconomic status was the most common risk 
 factor (44.8%) present in the population screened. 
CONVENTIONAL PAP SMEAR CYTOLOGY FINDINGS 
 All patients were subjected to conventional Pap smear cytology. 
 There were 7 cases (3.5%) which were inadequate, 20 Cases (10%) 
 showed normal findings,8 cases were atrophic (4%), 115 cases 
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 showed features of cervicitis (57.5%), 2 cases showed 
 ASCUS(1%),  11 Cases (5.5%) showed LSIL, 18 cases (9%) 
 showed HSIL. 17 cases (8.5%) showed squamous cell carcinoma 
 and 2 cases (1%) showed adenocarcinoma. 
 3.5% of cases were inadequate for interpretation in this study. 
  In a study by M Tunc Canda et al42 comparing the efficacy of 
 conventional pap smears and Liqui prep TM, 0.8% of conventional 
 smears were inadequate for interpretation. 
 Considering ASCUS and above as abnormal, 25% of the screened 
 population showed positive results. 
  In a study conducted at Pohang St Mary‟s Hospital62 involving 
 1235 women the percentage of cases which were ASCUS+ was 
 31%.   
LIQUID BASED CYTOLOGY FINDINGS: 
 All the 200 patients were subjected to liquid based cytology. 
 3 cases(1.5%) were inadequate, 20 cases(10%) normal, 9 
 smears(4.5%) were atrophic, 113 cases(56.5%) showed cervicitis, 
 15 cases(7.5%) were LSIL, 21 cases(10.5%) showed HSIL. 17 
 cases(8.5%) were squamous cell carcinomas and 2 cases(1%) were 
 adenocarcinomas. 
 In this study the rate of inadequate smears was 1.5%. 
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  In the study by M Tunc Canda et al42, Liquiprep smears were 
 inadequate only in 0.1%. 
 There were no cases of ASCUS in LBC.  
 Cases which were LSIL and above (27.5%) were considered 
 abnormal. 
  University of Zimbabwe _ JHPIEGO Cervical Cancer Project51 
 found that 14.6% of the women in their study had an abnormal Pap 
 smear. 
BIOPSY FINDINGS: 
 Biopsy was done in all cases which showed VIA/VILI positivity 
 and in cases which were ASCUS+ on Pap cytology.  
 Biopsy was not done in 8 low grade lesions on colposcopy as they 
 were negative for squamous intraepithelial lesion on both 
 conventional and liquid based cytology. 
 Biopsy was also done in 12 cases who showed no abnormal results 
 in VIA/VILI and pap smear as control. 
 22 cases (28.5%) showed cervicitis on biopsy, 16 cases (20.8%) 
 showed CIN 1, 14 cases (18.2%) showed CIN 2, 6 cases (7.8%) 
 were CIN 3, 1 case (1.3%) showed carcinoma in situ with focal 
 microinvasion. 16 cases (20.8%) revealed invasive squamous cell 
 carcinoma and 2 cases (2.6%) were adenocarcinoma.  
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 In the study conducted by Longatto filho et al63 in 2005 involving 
 10,000 women, the results of biospy were 2500 normal cases 
 (54%), 1860 inflammatory (42%), dysplasia in 80 cases (4%), mild 
 dysplasia (2%), moderate dysplasia (2%). 
AGEWISE DISTRIBUTION OF BIOPSY RESULT: 
 In this study the most common age group of CIN is 31-40 years 
 whereas invasive carcinoma is common above the age group of 50 
 years. 
  Kushtagi and Fernandes in their study showed the prevalence of 
 dysplasia was higher in women over 30 years
59
.  
 Shalini et al58 showed 25% of well differentiated and 35% of 
 moderately differentiated carcinomas in the age group 40-49, 50% 
 of well differentiated and 57% of moderately differentiated 
 carcinoma was in age group > 50. The mean age of patient with 
 cancer cervix was 41. 
COMPARISION OF VIA/VILI RESULTS WITH BIOPSY: 
 Among the 20 low grade lesions, 8 were cervicitis, 10 were CIN 1 
 and 2 cases were diagnosed as CIN 3 on biopsy.  
 21 high grade lesions were reported CIN 1: 3 cases, CIN 2: 12 
 cases and CIN 3: 6 cases.  
 Out of 19 cases of invasive carcinomas, 1 case was carcinoma in 
 situ, 16 cases were reported as SCC and 2 cases were reported as 
 adenocarcinoma on biopsy. 
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 In our study the sensitivity of VIA/VILI was 94.55%, specificity 
 was 63.64%, Positive predictive value was 86.67% and negative 
 predictive value was 82.35%. 
 The sensitivity, specificity, PPV and NPV of various studies are 
 tabulated below: 
STUDY SENSITIVITY 
% 
SPECIFICITY 
% 
PPV 
% 
NPV 
% 
Present study 94.55 63.64 86.67 82.35 
Divya Hedge  
et al
53
 (2011) 
70.8 95 96.5 62.9 
Shankaranarayanan 
et al
60
 (2001) 
90 92 17 97 
Zimbabwe/ 
JHPIEGO
51 
 
                     Phase I 
NA NA 25.9 73.3 
                    Phase II 76.7 64.1 18.6 73.3 
Goel et al
64
 (2005) 96.7 36.4 58 99.7 
Singh KN et al
65
 
(2010) 
93.1 86.8 22.1 99 
Bhatla N et al
66
 
(2007) 
100 53.3 15.7 100 
Rana T et al 93 90 62.5 98.8 
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 False positive cases were 8 cases of low grade lesions on 
 colposcopy reported as cervicitis on biopsy. 
 False negative cases were 2 cases of ectopy and one case of 
 satellite lesion on colposcopy which were CIN 1 on biopsy  . 
COMPARISION OF CONVENTIONAL PAP SMEAR WITH 
BIOPSY: 
 1 normal smear was reported as cervicitis on biopsy.  
 22 cases of cervicitis on Pap smear were given as cervicitis- 19 and 
 CIN 1- 3 on biopsy.  
 1 atrophic smear was reported as cervicitis. 3 inadequate smears 
 were reported as CIN 2- 2 and CIN 3- 1.  
 2 cases of ASCUS were CIN 1 on biopsy. 11 cases of LSIL were 
 given as CIN 1-10 and cervicitis- 1.  
 18 cases of HSIL turned out to be CIN 1- 2, CIN 2-11, CIN 3-5.  
 19 cases of invasive carcinoma were reported carcinoma in situ 
 with focal microinvasion- 1, SCC- 16 and adenocarcinoma- 2 on 
 biopsy. 
 The sensitivity, specificity, PPV and NPV of various studies are 
 tabulated below: 
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STUDY SENSITIVITY 
% 
SPECIFICITY 
% 
PPV 
% 
NPV 
% 
Present study 89.09 95.45 98 77.78 
Divya Hedge  
et al
53
 (2011) 
83 98 97.9 80 
Shankaranarayanan 
et al
60
 (2001) 
86 91 22 99 
Jang JH et al
62 
(1992-2001) 
82.7 95.5   
Goel et al
64
 (2005) 50 97 97.5 96.09 
Singh KN et al
65
 
(2010) 
70.02 97.2 51.2 97 
Hussein T et al
66 
92 76 57 96 
Mahmood Khaniki 
et al
67 
66 86 33 96 
Hua Chen et al
68 
43.08 97.2 70 91.85 
Nadereh Behtash
69 
58 88 33 96 
Rana T et al
70 
83.3 97 83 97 
 
 False positive was 1 case of LSIL on conventional pap smear 
 which was reported as chronic cervicitis on biopsy. 
 False negative cases were 6 cases: 2 cases of CIN 1 on biopsy were 
 reported as cervicitis on pap smear.1 case of CIN 1 was reported as 
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 inflammatory smear on pap. 2 cases of CIN 2 and 1 case of CIN 3 
 were inadequate for interpretation on conventional pap smear. 
COMPARISON OF LBC RESULTS WITH BIOPSY: 
 2 normal smears were reported as cervicitis on biopsy. 
 15 cases of cervicitis on LBC smear were given as cervicitis- 12 
 and CIN 1- 3 on biopsy.  
 2 atrophic smears were reported as cervicitis.  
 15 cases of LSIL were given as CIN 1-11, CIN 2- 1 and cervicitis-
 3.  
 21 cases of HSIL turned out to be CIN 1- 2, CIN 2-13, CIN 3-6.  
 19 cases of invasive carcinoma were reported as carcinoma in situ 
 with focal microinvasion- 1, SCC- 16 and adenocarcinoma- 2 on 
 biopsy. 
STUDY SENITIVITY 
% 
SPECIFICITY 
% 
PPV 
% 
NPV 
% 
Present study 94.55 86.36 94.55 86.36 
Hussein T et al
66
 83 82 62 93 
Mahmood 
Khaniki et al
67 
(Liquiprep TM) 
83 98 83 96 
Longatto Filho 
et al
68 
 
(ThinPrep) 
33.3 100 100 88.8 
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Hua Chen et al
68 
(ThinPrep) 
80 63.16 16 97.3 
Nadereh Behtash 
et al
69 
(Liquiprep TM) 
86 98.5 86 98.5 
Lee HS et al
71 
(Thin Prep) 
79 98   
Lee KC et al
72 
(Thin Prep) 
85.1 98.3   
Lee KC et al
73 
(Surepath TM) 
91.7 75.9   
Lim YK et al
74 
(MonoPrep) 
94.9 92.3   
 
There were 3 cases of false positive- reported as LSIL on LBC 
smear and cervicitis on biopsy. False negative cases were 3 cases which 
were CIN 1 on biopsy but reported as cervicitis on LBC. 
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COMPARISION OF VARIOUS SCREENING PROCEDURES: 
 The sensitivity was highest for both VIA/VILI and Liqui Prep TM 
 and was similar (94.55%). However the specificity was highest for 
 conventional pap smear (95.45%). 
 Positive predictive value was highest for conventional pap smear 
 (98%) followed by LiquiPrep TM (94.55%). 
 Negative predictive value was highest for LiquiPrep TM (86.36%) 
 followed by VIA/VILI (82.35%). 
 The percentage of false positives was highest with VIA/VILI 
 (36.36%) and lowest with conventional pap smear (4.55%). 
 The percentage of false negatives was highest with conventional 
 pap smear (10.91%) and both LiquiPrepTM and VIA/VILI showed 
 a lower percentage of false negatives (5.45%).  
COMPARISON OF CONVENTIONAL PAP AND  
LIQUIPREP TM: 
 Conventional pap smears were inadequate in 3.5% whereas 
 LiquiPrepTM smears were inadequate in 1.5%. 
 Hussein T et al66 showed that the rate of inadequacy was 4.3% for 
 conventional pap while it was 0.68% for LBC. 
 There were 115 cervicitis smears (57.5%) on conventional pap 
 smear but only 113 cervicitis  smears on LBC (56.5%). 
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 In a study by Nadereh Behtash et al69 conducted at Iran on 506 
 patients, 26% of conventional pap smears were inflammatory 
 whereas only 19% of LBC smears were inadequate. 
 In this study, the percentage of concordance of conventional pap 
 smear with biopsy was 100% for ASCUS, 90.1% for LSIL, 88.89% 
 for HSIL and 100% for invasive carcinoma. 
 In a study by Deshou et al75 at Jiangxi Province Women and Child 
 Health Care Hospital, the concordance rate of conventional smear 
 was 80% for ASCUS, 78.9% for LSIL, 76.1% for HSIL and 89.5% 
 for SCC. 
 Joonseok Park et al76  in a study comparing the efficacy of 
 conventional pap smear and Liquiprep TM, showed that the 
 concordance rate of conventional pap smear was 89.2% for LSIL 
 and 93.6% for HSIL. 
 In this study, the percentage of concordance of LiquiprepTM Pap 
 smear with biopsy was 80% for LSIL, 90.47% for HSIL and 100% 
 for invasive carcinoma. The lower concordance rate for LSIL could 
 be due to error in the sampling area for biopsy. 
 In a study by Deshou et al75, the concordance rate of conventional 
 smear  was 93.9% for ASCUS, 95.4% for LSIL, 90.2% for HSIL 
 and 94.7% for SCC. 
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 Joonseok Park et al76 in their study showed that the concordance 
 rate of conventional pap smear was 93.5% for LSIL and 95.5% for 
 HSIL. 
 In this study the detection rate of ASCUS is 1%, for  LSIL is 5.5% 
 and for HSIL is 9%  in conventional pap, whereas the detection 
 rate of LSIL is 7.5% and of HSIL is 10.5%. 
 Out of the 2 cases of ASCUS on conventional pap, one was 
 reported as cervicitis and another as LSIL on LBC. 
 In the study by Hussein T et al66 , the detection rates of HSIL were 
 similar for both conventional pap and LBC but the detection rate of 
 LSIL was greater for LBC (ThinPrepTM) compared to 
 conventional pap. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
SUMMARy
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SUMMARY 
 This is the study conducted at Kasturba Gandhi Hospital for 
 women and children to study the efficacy of VIA/VILI, 
 conventional pap and LBC with biopsy as gold standard in low 
 resource country like India.  
 VIA/VILI, conventional pap smear and liquid based cytology were 
 done in all 200 patients. 
 Those cases showing VIA/VILI Positive (or) cytology positive 
 were subjected to cervical biopsy except for 12 cases which were 
 negative on VIA/VILI and cytology for which biopsy was done (as 
 control). 
 Majority of women enrolled in the study belonged to the age group 
 of 31-40 years, were of socioeconomic grade 4 or 5, attained 
 menarche at 13-14 years of age, had their marriages around 15-20 
 years, were of parity 2. 
 The most common presenting symptom in the study group was 
 white discharge per vagina (63%). 
 VIA/VILI was positive in 68 cases (34%) and 132 cases (68%) 
 showed negative results. 
 39.7% of the patients who were VIA/VILI positive belonged to 31-
 40 years age group. 
 Majority of the patients who were VIA/VILI positive were of 
 socioeconomic grade 4 or grade 5. 
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 Pap smear report was inadequate in 7 patients (3.5%), normal in 20 
 patients (10%), atrophic smear in 8 patients (4%), Cervicitis in 115 
 patients (57.5%), ASCUS in 2 patients (1%), LSIL in 11 patients 
 (5.5%), HSIL in 18% (9%), SCC in 17 patients (8.5%) and 
 adenocarcinoma in 2 patients (1% ). 
 LBC report was inadequate in 3 patients (1.5%), normal in 20 
 patients (10%), atrophic smear in 9 patients (4.5%), Cervicitis in 
 113 patients (56.5%), LSIL in 15 patients (7.5%), HSIL in 21% 
 (10.5%), SCC in 17 patients (8.5%) and adenocarcinoma in 2 
 patients (1%). 
 Biopsy was reported as cervicitis in 22 cases (28.5), CIN 1 in 16 
cases (20.8%), CIN 2 in 14 cases (18.2%), CIN 3 in 6 cases (7.8%), 
carcinoma in situ with focal microinvasion in 1 case (1.3%), SCC in 
16 cases (20.8%) and adenocarcinoma in 2 cases (2.6%). 
 The most common age group of CIN is 31-40 years whereas 
 invasive carcinoma is common above the age group of 50 years. 
 Out of 20 low grade lesions, 12 showed dysplasia on biopsy. All 
 the 21 high grade lesions showed dysplasia on biopsy. 
 3 negative cases, 3 inadequate cases and both the cases of ASCUS, 
 and all cases of HSIL showed dysplasia on biopsy. Among the 
 cases of LSIL, 1 case failed to show dysplastic changes on biopsy. 
 This may be due to the error in the area sampled for biopsy. 
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 3 cases of cervicitis and all cases of HSIL showed dysplasia on 
 biopsy. Among the 15 LSIL cases, 12 were dysplastic on biopsy. 
 2 cases which were diagnosed as ASCUS on conventional pap 
 were reported as LSIL and cervicitis on LBC. 
 The percentage of concordance of conventional pap smear with 
 biopsy was 100% for ASCUS, 90.1% for LSIL, 88.89% for HSIL 
 and 100% for invasive carcinoma. 
 The percentage of concordance of Liquiprep TM pap smear with 
 biopsy was 80% for LSIL, 90.47% for HSIL and 100% for invasive 
 carcinoma. 
 Both VIA/VILI and LBC had similar sensitivity rates in the 
screening of cancer cervix compared to conventional Pap smear. 
However the specificity and PPV were highest for the conventional 
pap smear followed by LBC. Liquiprep TM had the highest 
negative predictive value.  
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CONCLUSION 
 This correlative study of  VIA/VILI, conventional pap smear and 
 LiquiPrepTM smear with histopathological examination of cervix 
 revealed that VIA/VILI and LiquiPrepTM had similar sensitivity of 
 94.55% which was higher than that of conventional pap smear. 
 Specificity was significantly higher with conventional pap smear 
 (95.45%). LiquiPrepTM had a lower specificity than conventional 
 pap, however it was higher than that of VIA/VILI. 
 Conventional pap and LiquiPrepTM had higher positive predictive 
 values whereas LiquiPrep TM had the highest negative predictive 
 value followed by VIA/VILI. 
 VIA/VILI showed the highest percentage of false positives while 
 the false negatives were highest with conventional Pap smear.  
 In conclusion, VIA/VILI can be used as an initial screening test for 
 cervical cancer in a low resource country like India. 
 The false negative and false positive cases in this study can be 
 minimized by proper screening and interpretation and further 
 follow up by cytological smears. 
 Conventional pap because of its high specificity can be used for 
 followup of low grade lesions on colposcopy. 
 LiquiPrepTM has a higher sensitivity equal to that of VIA/VILI 
 and a comparatively higher specificity compared to VIA/VILI and 
 therefore can be used for screening in conditions when there are no  
          financial constrains. 
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ANNEXURES
 ANNEXURE- I 
PROFORMA 
NAME                                
AGE  
OP/IP NO 
OCCUPATION 
SOCIOECONOMIC STATUS 
ADDRESS 
AGE AT MENARCHE 
AGE AT MARRIAGE 
PARITY 
LCB 
H/O SEXUALLY TRANSMITTED DISEASE 
PAST H/O HT/DM/ASTHMA/EPILEPSY/ TB 
PAST H/O SURGERY (ABDOMINAL) 
CONTRACEPTIVE HISTORY 
PERMANENT / TEMPORARY 
-STERILISATION: 
                                 Puerperal Sterilisation 
                                Trans abdominal tubectomy – {Interval or 
                                  Lap sterilization concurrent with MTP } 
                                Caesarian section with sterilization 
GENERAL EXAMINATION 
HEIGHT 
WEIGHT 
BUILD / NOURISHMENT 
ANEMIA JAUNDICE 
THYROID BREAST 
VITALS SIGNS:  PULSE RATE, BLOOD PRESSURE,     
RESPIRATORY RATE, TEMP 
SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM 
RESPIRATORY STYSTEM 
ABDOMINAL EXAMINATION 
SPECULUM EXAMINATION 
VISUAL INSPECTION WITH ACETIC ACID 
VISUAL INSPECTION WITH LUGOL’S IODINE 
CONVENTIONAL PAPSMEAR CYTOLOGY 
LIQUIPREPTM SMEAR CYTOLOGY 
BIOPSY REPORT 
FOLLOW UP ACTION 
 ANNEXURE- II 
THE BETHESDA SYSTEM (TBS) 2001 CLASSIFICATION 
ADEQUACY OF THE SPECIMENAdequacy 
Satisfactory for evaluation 
Unsatisfactory for evaluation 
GENERAL CATEGORISATIONGeneral 
Negative for intraepithelial lesion or malignancy 
Epithelial cell abnormalities 
Squamous Cell 
Atypical squamous cells (ASC) 
Atypical squamous cells – undetermined 
significance (ASCUS) 
Atypical squamous cells – cannot exclude HSIL (ASC-H) 
Low-grade squamous intraepithelial lesion (LSIL) encompassing human 
papillomavirus and mild dysplasia/CIN 1 
High-grade squamous intraepithelial lesion (HSIL) 
encompassing moderate and severe dysplasia, CIS/ CIN 2 and CIN 3 
Squamous cell carcinoma 
Glandular cell 
Atypical glandular cells 
Atypical glandular cells (unqualified) 
  
 
 
Atypical endocervical cells (unqualified) 
Atypical endometrial cells (unqualified) 
Atypical glandular cells, favor neoplastic 
Atypical endocervical cells, favor neoplastic 
Adenocarcinoma in situ (AIS) 
Endocervical adenocarcinoma 
Endometrial adenocarcinoma 
Adenocarcinoma, nonspecific 
Other 
Hormonal evaluation (applies to vaginal smears only) 
Hormonal pattern compatible with age and history 
Hormonal pattern incompatible with age and history (specify) 
Hormonal evaluation not possible because of. . .(specify) 
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MASTER CHART 
  
MASTER CHART 
S.NO PAP.NO AGE SE STATUS AGE AT MENARCHE AGE AT MARRIAGE PARITY SYMP-TOMS PS VIA VILI CONV PAP LBC BIOPSY 
1 1/11 43 3 14 20 2 WHITE DIS + _ _ OESTROG OESTROG  
2 2/11 40 4 13 36 0 WHITE DIS _ _ _ OESTROG OESTROG  
3 3/11 31 3 13 17 4 WHITE DIS + _ _ CERVICITIS CERVICITIS  
4 4/11 28 4 14 21 2 AUB + _ _ INFLAM OESTROG  
5 5/11 47 4 14 16 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
6 6/11 64 2 15 20 5 WHITE DIS _ _ _ ATROPH ATROPH CERVICITIS 
7 7/11 20 3 13 17 2 AUB + _ _ INFLAM INFLAM  
8 8/11 32 4 12 20 3 AUB _ _ _ CERVICITIS CERVICITIS  
9 9/11 35 4 13 24 3 WHITE DIS + HG HG HSIL HSIL CIN 2 
10 10/11 30 3 14 22 1 WHITE DIS _ _ _ CERVICITIS CERVICITIS  
11 11/11 30 5 13 21 2 WHITE DIS _ _ _ INFLAM CERVICITIS  
12 12/11 30 3 12 19 2 WHITE DIS _ _ _ INFLAM INFLAM  
13 13/11 47 4 13 20 3 AUB + _ _ INADEQ CERVICITIS  
14 14/11 28 5 13 18 2 WHITE DIS + _ _ OESTROG OESTROG  
15 15/11 29 4 13 19 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
16 16/11 35 5 12 33 1 WHITE DIS + _ _ CERVICITIS OESTROG CERVICITIS 
17 17/11 50 2 14 15 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
18 18/11 37 4 14 15 3 PRURITIS + _ _ CERVICITIS CERVICITIS  
19 19/11 47 4 13 17 2 WHITE DIS + _ _ INFLAM CERVICITIS  
20 20/11 42 3 13 20 3 WHITE DIS + LG LG INFLAM INFLAM CERVICITIS 
21 21/11 34 4 15 19 4 WHITE DIS + _ _ INFLAM CERVICITIS  
  
22 22/11 51 4 12 16 4 AUB + INV CA INV CA ADENO CA ADENO CA MD ADENO CA 
23 23/11 35 5 14 22 2 WHITE DIS + LG LG INFLAM CERVICITIS CERVICITIS 
24 24/11 39 5 12 27 2 WHITE DIS _ _ _ INFLAM INFLAM  
25 25/11 38 4 13 18 0 WHITE DIS _ _ _ CERVICITIS CERVICITIS  
26 26/11 42 3 16 24 3 WHITE DIS + _ _ NOR NOR  
27 27/11 48 4 13 16 2 AUB _ _ _ ATROPH ATROPH  
28 28/11 50 2 14 25 2 WHITE DIS + LG LG LSIL LSIL CERVICITIS 
29 29/11 40 4 14 18 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
30 30/11 39 3 13 19 2 WHITE DIS + LG LG CERVICITIS CERVICITIS  
31 31/11 27 5 13 18 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
32 32/11 60 4 13 25 1 WHITE DIS _ _ _ INFLAM INFLAM  
33 33/11 33 5 15 16 3 WHITE DIS + LG LG HSIL HSIL CIN 2 
34 34/11 50 4 13 15 5 AUB _ HG HG HSIL HSIL LG CIN 
35 35/11 41 3 14 19 3 WHITE DIS + _ _ INFLAM INFLAM  
36 36/11 30 4 14 16 4 WHITE DIS + HG HG HSIL HSIL CIN 1-2 
37 37/11 26 4 14 19 2 WHITE DIS + _ _ CERVICITIS INFLAM CERVICITIS 
38 38/11 35 3 13 20 2 WHITE DIS + HG HG HSIL HSIL CIN 2 
39 39/11 35 4 14 24 3 AUB + HG HG HSIL HSIL CIN 2 
40 40/11 47 2 15 17 4 AUB + INV CA INV CA SCC SCC MD SCC 
41 41/11 53 4 13 18 0 WHITE DIS _ INV CA INV CA SCC SCC PD SCC 
42 42/11 24 4 12 17 3 WHITE DIS + LG LG CERVICITIS CERVICITIS  
43 43/11 29 3 14 19 2 WHITE DIS + _ _ OESTROG CERVICITIS  
44 44/11 40 3 15 25 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
45 45/11 36 4 13 22 2 WHITE DIS + _ _ INFLAM INFLAM  
46 46/11 65 3 12 23 3 AUB _ POST 
MENO 
POST MENO ATROPH ATROPH  
  
47 47/11 32 4 14 23 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
48 48/11 41 4 13 24 2 WHITE DIS _ _ _ CERVICITIS CERVICITIS  
49 49/11 27 4 13 17 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
50 50/11 50 5 13 20 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
51 51/11 40 5 13 17 2 PRURITIS + _ _ INFLAM CERVICITIS  
52 52/11 41 3 11 16 3 WHITE DIS + _ _ INFLAM CERVICITIS  
53 53/11 48 4 14 18 2 PAIN ABD _ _ _ INFLAM CERVICITIS  
54 54/11 50 5 13 17 3 WHITE DIS _ _ _ INFLAM INFLAM  
55 55/11 30 4 13 16 2 WHITE DIS + _ _ INFLAM INFLAM  
56 56/11 47 5 14 17 4 AUB + POST 
MENO 
POST MENO ATROPH INADEQ  
57 57/11 55 4 13 20 3 AUB + INV CA INV CA SCC SCC PD SCC 
58 58/11 25 2 12 19 2 WHITE DIS + NOR NOR CERVICITIS CERVICITIS  
59 59/11 40 4 14 21 2 WHITE DIS + _ _ INFLAM CERVICITIS CERVICITIS 
60 60/11 35 4 14 17 2 WHITE DIS + LG LG CERVICITIS CERVICITIS CERVICITIS 
61 61/11 42 3 13 16 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
62 62/11 45 5 11 18 2 PAIN ABD _ _ _ NOR CERVICITIS  
63 63/11 40 3 13 18 3 WHITE DIS + LG LG NOR CERVICITIS CERVICITIS 
64 64/11 40 4 13 15 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
65 65/11 24 2 13 22 1 WHITE DIS _ _ _ INFLAM CERVICITIS  
66 66/11 26 4 12 16 3 AUB + LG LG INFLAM CERVICITIS  
67 67/11 44 4 13 20 2 WHITE DIS + HG HG HSIL HSIL CIN 2 
68 68/11 60 4 13 15 5 WHITE DIS _ POST 
MENO 
POST MENO INFLAM CERVICITIS  
69 69/11 62 4 14 19 3 AUB + POST 
MENO 
POST MENO CERVICITIS ATROPH CERVICITIS 
  
70 70/11 40 4 13 16 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
71 71/11 49 4 14 25 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
72 72/11 30 5 13 17 2 WHITE DIS + _ _ NOR CERVICITIS  
73 73/11 39 3 12 22 2 WHITE DIS + HG HG CERVICITIS CERVICITIS LG CIN 
74 74/11 36 4 13 25 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
75 75/11 40 4 12 16 3 POST COITAL 
BLEED 
+ INV CA INV CA ADENO CA ADENO CA PD ADENOCA 
76 76/11 65 4 13 16 6 AUB _ INV CA INV CA SCC SCC WD SCC 
77 77/11 63 4 13 23 3 AUB + POST 
MENO 
POST MENO ATROPH ATROPH  
78 78/11 42 4 14 17 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
79 79/11 45 5 13 21 3 WHITE DIS + _ _ CERVICITIS INFLAM CERVICITIS 
80 80/11 38 4 14 21 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
81 81/11 24 5 13 17 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
82 82/11 29 4 12 17 2 WHITE DIS + _ _ INFLAM OESTROG  
83 83/11 49 4 14 24 5 AUB + _ _ CERVICITIS CERVICITIS  
84 84/11 33 4 12 22 2 PRURITIS + _ _ INFLAM INFLAM  
85 85/11 40 5 12 20 2 WHITE DIS + _ _ PROGEST CERVICITIS  
86 86/11 40 4 13 25 2 AUB + _ _ PROGEST PROGEST  
87 87/11 29 5 12 18 3 AUB + _ _ INFLAM CERVICITIS  
88 88/11 35 4 13 18 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
89 89/11 43 5 14 19 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
90 90/11 51 4 13 20 3 AUB + _ _ ATROPH ATROPH  
91 91/11 30 5 12 16 2 WHITE DIS + _ _ OESTROG OESTROG  
  
92 92/11 45 5 13 26 2 PRURITIS + _ _ OESTROG CERVICITIS  
93 93/11 55 3 13 16 4 PAIN ABD + _ _ CERVICITIS CERVICITIS  
94 94/11 30 3 14 20 3 PAIN ABD + _ _ INFLAM OESTROG CERVICITIS 
95 95/11 35 4 14 23 3 WHITE DIS + _ _ INFLAM INFLAM  
96 96/11 28 2 13 17 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
97 97/11 20 5 13 18 1 WHITE DIS _ _ _ INFLAM INFLAM  
98 98/11 42 5 14 20 2 PAIN ABD + _ _ INFLAM INFLAM  
99 99/11 38 3 13 21 2 WHITE DIS + _ _ INFLAM INFLAM  
100 100/11 36 4 14 18 0 WHITE DIS _ _ _ CERVICITIS CERVICITIS  
101 101/11 32 4 12 16 2 PAIN ABD + LG LG CERVICITIS CERVICITIS CIN 1 
102 102/11 55 5 13 16 3 AUB _ INV CA INV CA SCC SCC MD SCC 
103 103/11 30 3 14 24 2 PAIN ABD + _ _ CERVICITIS CERVICITIS  
104 104/11 40 3 12 15 2 WHITE DIS + _ _ OESTROG OESTROG  
105 105/11 75 5 13 20 6 WHITE DIS _ ECTOPY ECTOPY CERVICITIS CERVICITIS CERVICITIS 
106 106/11 39 4 14 23 2 WHITE DIS + _ _ NOR NOR  
107 107/11 38 4 13 15 6 WHITE DIS + SATELLITE 
LES 
SATELLITE LES CERVICITIS LSIL CERVICITIS 
108 108/11 26 5 14 21 1 WHITE DIS _ ECTOPY ECTOPY LSIL LSIL CIN 1 
109 109/11 26 5 13 22 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
110 110/11 48 5 13 18 3 WHITE DIS + LG LG CERVICITIS CERVICITIS  
111 111/11 45 4 13 23 3 PRURITIS + NOR NOR CERVICITIS CERVICITIS  
112 112/11 23 4 12 18 1 AUB _ _ _ CERVICITIS CERVICITIS  
113 113/11 25 4 13 20 2 WHITE DIS + ECTOPY ECTOPY CERVICITIS CERVICITIS  
  
114 114/11 40 2 14 17 2 WHITE DIS + HG HG HSIL HSIL CIN 2-3 
115 115/11 55 4 13 17 3 AUB + LG LG ASCUS CERVICITIS CHRONIC CERVICITIS WITH FOCAL 
CIN 1 CHANGES 
116 116/11 40 5 13 18 3 WHITE DIS _ HG HG HSIL HSIL CIN 3 
117 117/11 40 4 12 16 3 WHITE DIS + HG HG HSIL HSIL CIN 2-3 
118 118/11 40 3 13 15 2 AUB + HG HG HSIL HSIL CIN 2 
119 119/11 60 3 14 15 3 AUB + INV CA INV CA SCC SCC SCC-WD KERATINISING 
120 120/11 55 5 13 17 2 AUB + INV CA INV CA SCC SCC SCC-MD LARGE CELL TYPE 
121 121/11 35 5 13 18 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
122 122/11 32 5 14 19 2 WHITE DIS + _ _ CERVICITIS CERVICITIS CERVICITIS 
123 123/11 34 3 13 19 2 PAIN ABD + HG HG HSIL HSIL CIN 2-3 
124 124/11 29 5 13 20 2 WHITE DIS + LG LG LSIL LSIL CIN 2 
125 125/11 45 4 15 17 5 PAIN ABD _ LG LG CERVICITIS CERVICITIS  
126 126/11 65 3 14 45 5 AUB _ INV CA INV CA SCC SCC SCC-WD KERATINISING 
127 127/11 35 5 14 25 4 WHITE DIS + ECTOPY ECTOPY LSIL LSIL CIN 1 
128 128/11 49 5 12 29 1 AUB + INV CA INV CA SCC SCC SCC-WD KERATINISING 
129 1/12 27 3 13 19 2 WHITE DIS + NOR NOR CERVICITIS CERVICITIS  
130 2/12 50 5 13 15 4 POST COITAL 
BLEED 
+ INV CA INV CA SCC SCC SCC-WD KERATINISING 
131 3/12 45 3 14 17 3 WHITE DIS + _ _ CERVICITIS INADEQ  
132 4/12 35 2 13 16 3 AUB _ HG HG INADEQ HSIL CIN 2 
133 5/12 40 4 13 18 3 WHITE DIS + HG HG HSIL HSIL CIN 2 
134 6/12 30 4 15 20 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
135 7/12 31 5 13 20 3 WHITE DIS + LG LG INFLAM LSIL CIN 1 
  
136 8/12 48 3 13 25 2 PAIN ABD + _ _ CERVICITIS CERVICITIS  
137 9/12 58 3 13 18 2 AUB _ INV CA INV CA SCC SCC CA IN SITU WITH FOCAL 
MICROINVASION 
138 10/12 55 5 13 19 8 WHITE DIS _ _ _ ATROPH ATROPH  
139 11/12 42 5 14 20 2 WHITE DIS + HG HG INADEQ HSIL CIN 2 
140 12/12 46 4 13 16 3 PAIN ABD + LG LG ASCUS LSIL CIN 1 
141 13/12 48 5 13 18 4 WHITE DIS + _ _ CERVICITIS CERVICITIS CERVICITIS 
142 14/12 51 5 14 17 5 WHITE DIS + _ _ CERVICITIS CERVICITIS  
143 15/12 37 3 13 17 1 PAIN ABD + _ _ CERVICITIS CERVICITIS  
144 16/12 30 4 13 22 0 PRURITIS _ _ _ CERVICITIS CERVICITIS  
145 17/12 28 5 13 18 2 WHITE DIS + LG LG CERVICITIS CERVICITIS  
146 18/12 34 5 12 23 3 WHITE DIS + _ _ CERVICITIS CERVICITIS  
147 19/12 52 5 13 16 1 AUB + _ _ ATROPH ATROPH  
148 20/12 45 5 13 15 3 PAIN ABD + _ _ NEG FOR SIL INADEQ  
149 21/12 54 3 14 22 5 AUB + INV CA INV CA SCC SCC PD SCC 
150 22/12 45 2 13 17 2 POST COITAL 
BLEED 
+ _ _ NEG FOR SIL NEG FOR SIL  
151 23/12 45 5 14 20 3 WHITE DIS + _ _ NEG FOR SIL NEG FOR SIL  
152 24/12 38 4 13 22 2 WHITE DIS + _ _ INADEQ NEG FOR SIL  
153 25/12 49 5 13 19 1 WHITE DIS _ _ _ CERVICITIS CERVICITIS  
154 26/12 49 5 14 20 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
155 27/12 30 3 13 17 2 WHITE DIS + _ _ INFLAM INFLAM  
156 28/12 59 2 14 19 3 PAIN ABD + _ _ INADEQ ATROPH  
157 29/12 35 3 13 19 2 AUB + _ _ CERVICITIS CERVICITIS  
158 30/12 44 3 13 19 2 PAIN ABD + ECTOPY ECTOPY INADEQ CERVICITIS  
159 31/12 50 5 14 20 1 WHITE DIS _ _ _ CERVICITIS CERVICITIS  
160 32/12 50 5 13 20 3 WHITE DIS + LG LG LSIL LSIL CIN 1 
  
161 33/12 45 5 13 25 2 PAIN ABD + SATELLITE 
LES 
SATELLITE LES CERVICITIS CERVICITIS  
162 34/12 35 5 12 17 2 WHITE DIS + _ _ INFLAM LSIL CERVICITIS 
163 35/12 25 4 13 17 2 WHITE DIS + LG LG CERVICITIS NEG FOR SIL  
164 36/12 55 3 14 19 3 AUB + SATELLITE 
LES 
SATELLITE LES LSIL LSIL CIN 1 
165 37/12 25 3 13 20 1 WHITE DIS _ LG LG CERVICITIS CERVICITIS  
166 38/12 50 5 14 16 2 WHITE DIS + POST 
MENO 
POST MENO INFLAM CERVICITIS  
167 39/12 43 5 14 30 2 PAIN ABD _ NOR NOR INFLAM NEG FOR SIL  
168 40/12 45 3 12 16 5 PAIN ABD _ _ _ CERVICITIS CERVICITIS  
169 41/12 55 5 13 22 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
170 42/12 40 4 14 25 2 WHITE DIS + _ _ CERVICITIS CERVICITIS  
171 43/12 46 5 13 20 2 WHITE DIS + HG HG HSIL HSIL CIN 2 
172 44/12 41 3 13 21 2 PRURITIS + _ _ CERVICITIS CERVICITIS CERVICITIS 
173 45/12 36 5 13 17 2 WHITE DIS + _ _ NOR NOR  
174 46/12 28 3 14 21 0 WHITE DIS _ NOR NOR PROGEST PROGEST  
175 47/12 39 3 13 17 1 WHITE DIS _ _ _ PROGEST PROGEST  
176 48/12 42 5 13 20 1 WHITE DIS _ NOR NOR CERVICITIS CERVICITIS  
177 49/12 32 4 14 20 2 PAIN ABD + POLYP POLYP CERVICITIS CERVICITIS  
178 50/12 50 4 14 38 2 WHITE DIS + NOR NOR CERVICITIS CERVICITIS  
179 51/12 38 5 13 18 2 PAIN ABD + ECTOPY ECTOPY CERVICITIS CERVICITIS  
180 52/12 29 5 13 19 2 WHITE DIS + SATELLITE 
LES 
SATELLITE LES INFLAM CERVICITIS  
181 53/12 32 3 13 22 2 WHITE DIS + LG LG LSIL LSIL CIN 1 
182 54/12 35 5 15 20 1 WHITE DIS _ _ _ CERVICITIS CERVICITIS CERVICITIS 
183 55/12 40 5 13 15 3 AUB + INV CA INV CA SCC SCC WD SCC-LARGE CELL TYPE 
184 56/12 41 3 14 19 1 AUB _ HG HG HSIL HSIL CIN 2 
  
185 57/12 46 4 13 17 2 WHITE DIS + LG LG LSIL LSIL CHRONIC CERVICITIS WITH FOCAL 
CIN 1 CHANGES 
186 58/12 32 5 13 17 2 WHITE DIS + LG LG LSIL LSIL CHRONIC CERVICITIS WITH FOCAL 
CIN 1 CHANGES 
187 59/12 38 3 13 16 2 PAIN ABD + LG LG CERVICITIS CERVICITIS CERVICITIS 
188 60/12 36 5 14 20 2 WHITE DIS + LG LG LSIL LSIL CIN 1 
189 61/12 42 5 13 18 3 WHITE DIS + HG HG HSIL HSIL CIN 2 
190 62/12 50 5 13 19 3 AUB + HG HG HSIL HSIL CIN 2-3 
191 63/12 45 4 14 20 2 WHITE DIS + LG LG LSIL LSIL CIN 1 
192 64/12 32 3 13 24 2 PAIN ABD + NOR NOR CERVICITIS CERVICITIS  
193 65/12 40 3 13 18 4 WHITE DIS + LG LG INFLAM CERVICITIS CERVICITIS 
194 66/12 39 4 14 19 1 PAIN ABD _ HG HG INADEQ HSIL CIN 2-3 
195 67/12 55 4 13 20 3 AUB + INV CA INV CA SCC SCC PD SCC 
196 68/12 36 5 14 18 3 POST COITAL 
BLEED 
+ INV CA INV CA SCC SCC MD SCC 
197 69/12 65 5 15 19 5 AUB _ INV CA INV CA SCC SCC PD SCC 
198 70/12 28 3 14 18 3 WHITE DIS + HG HG HSIL HSIL CIN 1 
199 71/12 60 4 14 16 5 PAIN ABD _ INV CA INV CA SCC SCC PD SCC 
200 72/12 46 2 13 22 2 WHITE DIS + LG LG INFLAM CERVICITIS CERVICITIS 
  
KEY TO MASTER CHART 
SE STATUS  : Socioeconomic status 
 
PS   : Puerperal sterilisation 
 
CONV PAP  : Conventional Pap smear 
 
WHITE DIS  : White discharge per vagina 
AUB   : Abnormal uterine bleeding 
PAIN ABD  : Pain abdomen 
LG   : Low grade lesion 
HG   : High grade lesion 
INV CA  : Invasive carcinoma 
POST MENO  : Postmenopausal changes 
NOR   : Normal 
SATELLITE LES : Satellite lesion 
INADEQ  : Inadequate smear 
ATROPH  : Atrophic smear 
INFLAM  : Inflammatory smear 
NEG FOR SIL : Negative for Squamous Intraepithelial Lesion 
OESTROG  : Oestrogenic phase 
PROGES  : Progestrogenic phase 
ADENOCA  : Adenocarcinoma 
CA IN SITU  : Carcinoma in situ 
LG CIN  : Low grade Cervical Intraepithelial Neoplasia 
MD ADENOCA : Moderately differentiated Adenocarcinoma 
PD ADENOCA : Poorly differentiated Adenocarcinoma 
WD SCC  : Well differentiated Squamous Cell Carcinoma 
MD SCC  : Moderately differentiated Squamous Cell Carcinoma 
PD SCC  : Poorly differentiated Squamous Cell Carcinoma 
 
  ABSTRACT  
 
INTRODUCTION: 
Carcinoma cervix is one of the leading causes of death among women in 
developing countries. For each case of cancer of body of the uterus, there are 25 
cases of cancer cervix in India. About 5,00,000  new cases of carcinoma cervix 
are being diagnosed each year out of which 79% occur in the developing 
countries.  
AIM: 
By virtue of its accessibility, cancer of cervix can be readily diagnosed in 
its precancerous stage. If treated in the earlier stages the patient can often be 
cured of the disease. There are various methods of screening for carcinoma 
cervix. 
The aim of this study is to compare the efficacy of VIA, VILI, 
conventional Pap smear and LiquiPrep
TM
 as screening procedure for carcinoma 
cervix in patients attending the Gynecology department of Institute of social 
obstetrics and Govt. Kasturba Gandhi hospital,Chennai and to correlate the 
cytological findings with histopathological diagnosis. 
MATERIALS AND METHODS:  
VIA, VILI, conventional pap smear cytology and liquid based cytology 
was done in all cases. Both conventional and liquid based cytology smears were 
stained by routine Pap stain. Those cases showing VIA/VILI Positive (or) 
cytology positive were subjected to cervical biopsy. For few VIA/VILI 
Negative cases, biopsy was done (as control). 
RESULTS:  
Both VIA/VILI and LBC had similar sensitivity rates in the screening of 
cancer cervix compared to conventional pap smear. However the specificity and 
PPV were highest for the conventional pap smear followed by Liquiprep
TM
. 
Liquiprep
TM
 had the highest negative predictive value. 
CONCLUSION:  
In conclusion, VIA/VILI can be used as an initial screening test for 
cervical cancer in a low resource country like India. The false negative and false 
positive cases in this study can be minimized by proper screening and 
interpretation and further follow up by cytological smears. Conventional pap 
because of its high specificity can be used for followup of low grade lesions on 
colposcopy. LiquiPrep
TM
 has a higher sensitivity equal to that of VIA/VILI and 
a comparatively higher specificity compared to VIA/VILI and therefore can be 
used for screening in conditions where there are no financial constraints.  
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